CMPX / tovecimig-biliary-tract-cancer — Tovecimig (CTX-009) for previously treated biliary tract cancer
Program analysis ·
bpiq_drug_id17398 · Mode A (prospective) · prepared 2026-10 · search date 2026-10-17 · USD · framework v6.2.0 · Coverage: CLEAREDAsset. Tovecimig · CTX-009, ABL001, NOV1501, TR009, ES104 · no brand name · sponsor Compass Therapeutics, under an exclusive global licence (excluding South Korea) from ABL Bio; Handok holds South Korea; Compass out-licensed China to Elpiscience [1][2] Biology and modality. DLL4 and VEGF-A · one antibody that blocks two signals tumours use to grow blood vessels · modality
bispecificIndication. Biliary tract cancer (bile-duct and gallbladder cancer) · second line, after gemcitabine and platinum chemotherapy · no biomarker selection · therapeutic areaoncology· orphan status US yes, EU unknown Status. Phase 2/3 · COMPANION-002 (NCT05506943) [3] · Fast Track (2024-04-25) and Orphan Drug (announced by 2026-04-08) · no approval anywhere Launch markets. United States only. The filings describe no EU, UK or Japan launch plan [2]Company context, financials, ownership, options and the full pipeline:
../company.md.How to read this. Written for a curious reader with little or no background in science, medicine, the drug industry or finance. Terms specific to this program are explained in the Glossary below. General terms are explained once in the glossary. All money figures are in US dollars (USD). Every fact carries one of three tags.
[VERIFIED — source]means a primary source confirmed it, and the source is named.[UNVERIFIED]means it could not be confirmed.[WEB ESTIMATE — source, date]means it is a third-party figure or a labelled model.Confidence legend. Every conclusion carries a confidence beside it (
01-rules.mdrule 1). A conclusion is a judgement drawn from several facts: a score, a rating, an answer to a Go / No-Go question, or a verdict. High means the evidence under it is primary, consistent and recent. Medium means the evidence is partial, indirect or mixed. Low means the judgement rests mostly on inference or on sources that could not be verified.Sources. Every source is cited as a number in square brackets,
[n]. The numbers run through the document in the order of first use. The Sources list at the end gives one link per number (01-rules.mdrule 20). “No public record as of 2026-10-17” means a search on that date found nothing.
This is a refresh. It replaces the 2026-08-19 document, which was written to framework 5.10.3. It re-ran the company tier and the program tier of the sweep in full. It keeps the earlier version’s corrections, its audit trails for rejected inputs and its analyses of past events, and it marks where this sweep corrected them. The largest change since August is the FDA feedback of 2026-09-22: the agency recommended a trial showing that patients live longer before Compass files for approval [4].
Glossary
| Term | Plain-language meaning |
|---|---|
| Tovecimig (also CTX-009, ABL001, NOV1501, TR009, ES104) | The drug. One antibody built with two kinds of binding arm, one for VEGF-A and one for DLL4. The code ABL001 is also used by Novartis for an unrelated leukaemia drug (asciminib), which is why searches on that code return the wrong papers. |
| Biliary tract cancer (BTC) | Cancer of the tubes that carry bile from the liver to the gut, and of the gallbladder. Four subtypes: intrahepatic cholangiocarcinoma (inside the liver), extrahepatic cholangiocarcinoma (outside it), gallbladder cancer, and ampullary cancer (where the bile duct meets the small intestine). |
| Cholangiocarcinoma | Cancer of the bile duct itself, the first two subtypes above. Often used loosely for all biliary tract cancer; it is not the same thing. |
| DLL4 (delta-like ligand 4) | A protein on blood-vessel cells inside a tumour. It switches on the Notch signal, which controls how new vessels branch and mature. |
| VEGF-A (vascular endothelial growth factor A) | The main protein a tumour releases to make new blood vessels grow toward it. |
| Bispecific antibody | An antibody built to grip two different targets at once. Tovecimig grips VEGF-A with its main body and DLL4 with two small fragments fixed to its ends. |
| COMPANION-002 (NCT05506943) | The pivotal trial: tovecimig plus paclitaxel against paclitaxel alone, in patients whose cancer grew after one earlier chemotherapy. |
| COMPANION-003 (NCT05513742) | A separate, finished Phase 2 of tovecimig in colorectal cancer. It did not advance. Not this program. |
| Paclitaxel | An old, cheap chemotherapy that stops cells dividing. Both arms of COMPANION-002 receive it. |
| FOLFOX | A chemotherapy combination (folinic acid, fluorouracil and oxaliplatin). The ABC-06 trial made it the usual second-line treatment. |
| ABC-06 | The randomised UK trial in which FOLFOX beat symptom care alone in second-line biliary tract cancer, by 0.9 months of median survival [5]. |
| Crossover | A trial rule that lets a patient whose cancer grows on the control arm switch to the new drug. It is humane, and it blurs the survival comparison, because the control group stops being a pure control. 54% of COMPANION-002 control patients crossed over. |
| RPSFT (rank-preserving structural failure time) | A standard statistical method that estimates what the control group’s survival would have been if nobody had crossed over. |
| ESMO Congress | The European Society for Medical Oncology’s yearly meeting. The 2026 meeting runs 23–27 October in Madrid. |
| Proffered Paper | ESMO’s highest-visibility abstract category: a podium talk followed by a named expert discussant who critiques the data in public. |
| Abstract 459O | ESMO’s number for the COMPANION-002 talk [6]. |
| ABL Bio | The South Korean company that invented the molecule and licensed it to Compass in 2018. It is owed royalties and milestone payments. |
Executive scorecard
Asset snapshot
| Asset snapshot | |
|---|---|
| Asset and sponsor | Tovecimig (CTX-009), Compass Therapeutics; licensed from ABL Bio (global excluding South Korea), China sub-licensed to Elpiscience, South Korea with Handok [1][2] |
| Modality and mechanism | bispecific; an IgG antibody against VEGF-A with two single-chain fragments against DLL4 fused to its ends; blocks two blood-vessel growth signals at once [7] |
| Targeted indications (Mode A) | Unresectable, advanced or metastatic biliary tract cancer after one gemcitabine-platinum regimen, all comers, no biomarker [3] |
| Stage and mode | Phase 2/3 (COMPANION-002 completed its primary and secondary analyses) · Mode A |
| Next catalysts (Mode A) | ESMO oral presentation of the full COMPANION-002 dataset, including duration of response, 2026-10-24 (window 2026-10-23 to 2026-10-27, see Readout) [8]. Then further FDA engagement; a BLA targeted for the first quarter of 2027 per secondary reports only [9] |
| Asset verdict | Pass — see below |
Domain scores
The weights are v2.2’s defaults [UNVERIFIED — default weight]. Every figure below is computed by
lib/scorecard.mjs from the criterion scores in A.2, A.5, M.6, B.1 and B.3 and from the three direct
scores.
| Domain | Sections | Weight | Score (1–10) | Rating | Key driver (one line) |
|---|---|---|---|---|---|
| Scientific rationale | A.1–A.2 | 15% | 3.7 | red | DLL4 has no genetic link to this disease and no anti-DLL4 drug has been approved; 44% severe high blood pressure |
| Clinical data and design | A.3 | 20% | 4.0 | amber | A randomised trial met response rate and progression-free survival, but survival was flat (hazard ratio 1.05) |
| Regulatory pathway | A.4 | 10% | 3.0 | red | The FDA recommended a survival trial before any marketing application (2026-09-22) |
| Operations and CMC | A.5, M | 10% | 5.1 | amber | Enrolment done; manufacturing at unnamed contract sites; guidance slipped repeatedly |
| Competitive position | B.1 | 15% | 5.5 | amber | First of its kind for the 70–80% without a targetable mutation, but no survival edge over FOLFOX |
| Market access | B.2–B.3 | 15% | 3.2 | red | Compared with paclitaxel, not FOLFOX; no survival benefit; no quality-of-life data |
| Risk profile (10 = low risk) | C | 15% | 3.0 | red | Regulatory and efficacy risks are both likely and severe |
| Weighted total | 100% | 3.9 | red |
Key metrics
| Key metric | Low | Base | High | Source or assumption [n] |
|---|---|---|---|---|
| Probability of success to the next phase (A.6) | 30% | 45% | 60% | The next phase is a filing; base rate 47.7% (BIO 2021, oncology, Phase III to filing), cut for the FDA recommendation, held up by the company’s stated intent to file [4] |
| Probability of success to approval (A.6) | 5% | 12% | 22% | Base rate 43.9% to approval, cut hard for the FDA’s request for a survival trial [4][10] |
| Peak sales, USD per year (B.4a) | $50M | $146M | $312M | Bottom-up US model, conditional on approval [UNVERIFIED — modelled] |
| eNPV, USD (B.4b) | −$60M | +$5M | +$250M | Risk-adjusted, after the cost of a survival trial [UNVERIFIED — modelled] |
| Market Access Score (B.3) | 3.2 | Mean of the five B.3 criteria, lib/scorecard.mjs |
Top-3 box
- Top-3 value drivers. 1. A randomised trial met its primary endpoint: response rate 18.0% against 5.3% [4]. 2. Progression-free survival nearly doubled, 4.7 against 2.6 months (hazard ratio 0.44) [4]. 3. No approved drug serves the 70–80% of second-line patients without a targetable mutation, and the drug holds Orphan Drug and Fast Track designations [5][11].
- Top-3 risks, each with its mitigation. 1. The FDA wants a survival trial before a filing [4]; mitigation: further FDA engagement, which the company says it is pursuing [4]. 2. Survival was flat and the crossover-adjusted figure was worse (hazard ratio 1.13) [12]; mitigation: none in the current data. 3. Severe high blood pressure in 44% of patients [12]; mitigation: standard blood pressure drugs, untested as a fix at scale.
- Evidence gaps, and whether each is still fixable at this stage. 1. Duration of response is unpublished. Fixable on 2026-10-24. 2. No peer-reviewed clinical result exists. Fixable by publication within months. 3. No survival benefit and no quality-of-life data. Fixable only by a new trial, which takes years and money the company has not said it will spend.
Asset verdict
Asset verdict: Pass. The regulator has said the current data are not enough to file, and the survival result gives no sign that a new trial would succeed. Monitor only if the 2026-10-24 duration figure is strong and the FDA later accepts a filing, or a partner funds the survival trial. · confidence Medium
This verdict judges the drug’s long-term value. It did not set any of the three scored calls in
Locked prediction (01-rules.md rule 45).
Visual 1: the seven domain scores

Source(s): the domain table above, computed by lib/scorecard.mjs from the scores in A.2, A.3,
A.4, A.5, M.6, B.1, B.3 and C [4][12][3][1]
Visual 2: milestones

Source(s): CT.gov [3]; Compass releases [4][8][12]; designation coverage [11][13]; BLA target from secondary reports only [9]
Visual 2b: clinical study timeline

Source(s): dates and n from CT.gov [3] and the design paper [7]; NCT06548412, NCT05513742, NCT07392957 and NCT07662031 from CT.gov search, read 2026-10-17. Date basis: registry dates as of the search date. COMPANION-002’s bar runs to its registry primary completion date, 2027-08-31, which moved from 2026-12-01 between the two sweeps (see Readout).
Studies supporting key target-profile claims.
- COMPANION-002 [4][12][3]: the response-rate, progression-free survival, survival and safety claims in A.1.
- The Korean Phase 1b/2 with paclitaxel (NCT04492033) [7]: the 6.9-month duration of response and the 37.5% response rate used as reference points.
- The first-in-human study (NCT03292783) and its population pharmacokinetic model [7][14]: the 10 mg/kg dose and the dosing claims.
Rationale for the clinical development plan. Compass ran one randomised Phase 2/3 trial with response rate as its primary endpoint. That design aimed at accelerated approval, as three other second-line biliary drugs have won it [15][16][17]. Allowing crossover protected patients and gave away the survival comparison, which is now the FDA’s main concern [4].
Key Go / No-Go to the next decision point. The next decision is a filing (A.3, filing column). Go: a median duration of response of 5 months or more on 2026-10-24, and an FDA position that accepts a filing on response rate and progression-free survival. No-Go: a duration below the 4.7-month median progression-free survival, or an FDA position that keeps a survival trial as a condition. The FDA position is undated; the company said on 2026-09-22 it would “further engage” [4].
Clinical pharmacology studies
| Study (ID or NCT) | Type | Design and n | Key finding | Label or dosing impact | Source |
|---|---|---|---|---|---|
| NCT03292783 | Dose escalation (RP2D) | Phase 1 monotherapy, nine dose levels 0.3–17.5 mg/kg, n=45 | No dose-limiting toxicity; responses at ≥10 mg/kg; 10 mg/kg carried forward [VERIFIED — design paper] | 10 mg/kg on days 1 and 15 of 28 | [7] |
| — | Drug–drug interaction | Not conducted | No public record as of 2026-10-17 | None known | [3][7] |
| — | QTc | No dedicated study | COMPANION-002 excluded patients with QTcF above 450 ms [VERIFIED — CT.gov] | None known | [3] |
| — | Hepatic or renal impairment | Not conducted | Trial required bilirubin ≤1.5× the upper normal limit and creatinine clearance ≥30 mL/min [VERIFIED — CT.gov] | Untested in severe organ impairment | [3] |
| NCT03292783 data | Population PK and exposure–response | Model on 712 samples from 30 patients | Two-compartment model; body weight the only covariate; fixed and weight-based doses give equal exposure; 15 mg/kg every 3 weeks matches 10 mg/kg every 2 weeks. No exposure–response model [VERIFIED — PubMed] | Supports a less frequent schedule, not yet tested | [14] |
| — | Dose optimisation | Not conducted | No randomised comparison of two doses, which the FDA’s Project Optimus asks for in oncology. No public record as of 2026-10-17 | A possible review question | [3] |
| — | Immunogenicity, food effect, ADME, ethnic bridging | Not reported | No public record as of 2026-10-17. Food effect does not apply to an infused antibody | None known | [7][14] |
0. Program-tier coverage — CLEARED
Every mandatory row was called. Company-tier coverage is in ../company.md C.0.
The manufacturing tier was run, because the program sits at its filing decision after a
Phase 2/3 pivotal trial. The payer tier was not, because the launch plan names no EU, UK or
Japan market [2]. The regulatory tier was not, because the catalyst is a congress
presentation, not a regulatory decision.
| Tool | State | Note / verbatim error |
|---|---|---|
CT.gov search_trials + get_trial_details on the pivotal NCT | CALLED | search_trials on “CTX-009 OR tovecimig OR ABL001” returned 63 trials, most of them Novartis’s asciminib, which shares the code ABL001; the 5.10.3 query without ABL001 had found the 6 tovecimig trials. get_trial_details on NCT05506943 returned 168 patients, 34 US sites, six outcome measures, primary_completion_date 2027-08-31 (2026-12-01 on 2026-08-19), has_results false, and no investigator names. |
PubMed search_articles + get_article_metadata on every hit | CALLED | A first query including “ABL001” returned 389 hits, the asciminib collision 02-connectors.md warns about for short codes. A restricted query returned the same 4 papers as in August. Metadata was retrieved for all 4, author lists included. |
Open Targets search_entities | CALLED | Returned DLL4 (ENSG00000128917), VEGFA (ENSG00000112715), cholangiocarcinoma (MONDO_0019087), biliary tract cancer (MONDO_0003060) and tovecimig (CHEMBL6068308). No throttle message this time. A follow-up association query found no DLL4 association with either disease, and VEGFA scores of 0.152 (cholangiocarcinoma) and 0.118 (biliary tract cancer) [18]. |
ChEMBL compound_search | CALLED | CHEMBL6068308 TOVECIMIG, “Antibody”, max_phase 2, USAN stem -mig [19]. ChEMBL’s small-molecule activity tables do not answer an antibody’s selectivity question, so the absence of binding data costs nothing here. |
| web_search ×4: peak sales · competitive · exclusivity + royalty · analyst | CALLED | Peak sales: one analyst figure found, William Blair’s $1.46 billion worldwide, rejected in B.4a with its audit trail. Competitive: second-line options and pipeline. Exclusivity and royalty: the 10-K and 10-Q answered both (patents from 2033; tiered single-digit royalties). Analyst: post-2026-09-22 rating changes, recorded in ../company.md C.8. |
| B.1a competitor efficacy and side-effect search (v2.2 prompt P4) | CALLED | Primary papers retrieved through PubMed for ABC-06, NIFTY, HERIZON-BTC-01, FIGHT-202, FOENIX-CCA2 and ClarIDHy [5][20][21][22][23][24]. |
| Orange Book and Purple Book | CALLED | Web search. Tovecimig is an unlicensed biologic, so it has no Purple Book entry yet. Orange Book entries for the small-molecule competitors were reached only through third-party mirrors and are not used [25]. |
| DailyMed | CALLED | API. Current labels read for zanidatamab (Ziihera), pemigatinib (Pemazyre), futibatinib (Lytgobi), ivosidenib (Tibsovo) and durvalumab (Imfinzi) [15][16][17][26][27]. |
| ICER | CALLED | Web search. No ICER assessment of a biliary tract cancer drug was found as of 2026-10-17 [28]. |
| CMS Medicare drug price negotiation page | CALLED | Web search. The 2025 law widened the orphan exclusion [29][30]. |
| optional EDGAR full-text search on the drug’s names | NOT CALLED | Optional row. The 10-K, 10-Q and 8-K were read directly from EDGAR instead. |
optional Europe PMC search | NOT CALLED | Optional row. PubMed answered with full metadata. |
optional CTIS search | NOT CALLED | Optional row. All 34 COMPANION-002 sites are in the US [3]. |
| Manufacturing tier: CMC search (v2.2 prompt P5) | CALLED | Two web searches on tovecimig with CRL, Form 483, warning letter, shortage, recall and contract-manufacturer terms. No contract manufacturer is named anywhere. No public record of a CMC problem as of 2026-10-17. |
| Manufacturing tier: openFDA CRL data | CALLED | API. “Compass”, “ABL” and “tovecimig” return NOT_FOUND. The endpoint itself answers (458 letters in total), so the empty result is real [31]. |
| Manufacturing tier: openFDA CRL web page | CALLED | Read through a web search on the sponsor’s name. No letter found. |
| Manufacturing tier: FDA warning letters | CALLED | Web search on the sponsor’s name. None found. The contract site is unnamed, so no site-level search could be run. |
| Manufacturing tier: FDA inspections dashboard | CALLED | Web search, as the method column directs. No record found. Same limit as the row above. |
| Manufacturing tier: openFDA drug shortages | CALLED | API. Tovecimig and paclitaxel return NOT_FOUND; the endpoint holds 1,581 records, so the result is real [32]. |
A. Scientific and clinical value
A.1 Target product profile
Target label. Tovecimig plus paclitaxel for adults with unresectable advanced, metastatic or recurrent biliary tract cancer whose disease progressed after one gemcitabine- and platinum-containing regimen, and who are not eligible for a targeted drug [3].
| Attribute | Minimum viable | Competitive (base) | High case | Standard of care and key competitors, data [n] | Current evidence for tovecimig [n] | Rating · confidence |
|---|---|---|---|---|---|---|
| Indication and population | Second line, all comers | Second line, all comers | Second line plus first line | FOLFOX for all comers [5]; zanidatamab (HER2), pemigatinib and futibatinib (FGFR2), ivosidenib (IDH1) for marker-selected patients [15][16][17][26] | Second line, all comers; excludes patients eligible for a targeted drug [3] | green · High |
| Mechanism and differentiation | A new mechanism with a plausible rationale | First in class with clinical proof | Best in class across angiogenesis drugs | No anti-angiogenic drug is approved in this disease | First DLL4 × VEGF-A bispecific in a pivotal trial; no anti-DLL4 drug has ever been approved [19] | amber · Medium |
| Efficacy (primary and key secondary endpoints) | Response rate above FOLFOX’s with no survival harm | Response rate and progression-free survival gains plus a survival trend | A survival benefit | FOLFOX: survival 6.2 against 5.3 months on symptom care (hazard ratio 0.69) [5]; nal-IRI + 5-FU: progression-free survival 4.2 against 1.7 months (hazard ratio 0.61) [20] | Response rate 18.0% against 5.3%; progression-free survival 4.7 against 2.6 months (hazard ratio 0.44); survival 8.9 against 9.4 months (hazard ratio 1.05) [4][12] | red · High |
| Safety and tolerability | Manageable, no new class signal | Grade 3+ rate near FOLFOX’s | Better tolerated than FOLFOX | FOLFOX: grade 3–5 adverse events 69% against 52% on symptom care [5] | High blood pressure 69% all grades, 44% grade 3+; neutropenia 36% grade 3+; fatigue 67% [12] | red · Medium |
| Dose, regimen, route, formulation | Intravenous, standard infusion | Same visits as the comparator | Every three weeks | FOLFOX every two weeks, intravenous [5] | Intravenous 10 mg/kg every two weeks with weekly paclitaxel; a three-weekly schedule is modelled, not tested [14] | amber · Medium |
| Biomarker or companion diagnostic | None needed | None needed | A marker that picks responders | Competitors need HER2, FGFR2 or IDH1 tests [15][16][17][26] | None tested or planned [3] | amber · Medium |
| Payer value (B.3) | Reimbursed at an orphan price | Reimbursed without restriction | Premium price on a survival gain | FOLFOX is generic | No survival gain and no quality-of-life data; Market Access Score 3.2 (B.3) | red · Medium |
Stakeholder check
| Stakeholder | What they require | Does the competitive profile meet it? (tagged) | Basis [n] |
|---|---|---|---|
| Patient and caregiver | Benefit the patient notices; convenience | Partly. Two more months before the cancer grows, at the cost of severe high blood pressure in 44% and no longer life [VERIFIED — Compass 2026-04-27] · Medium | [12] |
| Regulator | A favourable balance of benefit against risk | No, as of 2026-09-22. The FDA recommended a trial showing a survival benefit before a filing [VERIFIED — 8-K exhibit 99.1] · High | [4] |
| Payer and HTA body | Added benefit against the comparator, at a price they accept | No. The trial compared against paclitaxel, not FOLFOX, and shows no survival gain [UNVERIFIED — judgement] · Medium | [3][5] |
| Prescriber | A fit in treatment guidelines; ease of use | Partly. It would fill the all-comer gap, but blood-pressure management adds work [UNVERIFIED — judgement] · Medium | [12] |
Value link. No sourced figure exists for what a response-rate gain is worth in this disease.
The illustrative oncology link in 07-benchmarks.md § Rules of thumb values each extra month of
overall survival at roughly $150–300 million of peak sales [UNVERIFIED — illustrative]. Applied
here it gives nothing, because the survival gain is zero. Kept from the 5.10.3 version, which
stated the same unflattering result.
A.2 Rationale and evidence
Tovecimig is one antibody with two jobs. Its main body binds VEGF-A, the protein a tumour
releases to make blood vessels sprout toward it. Two small fragments on its ends bind DLL4 on
the vessel cells inside the tumour [7]. When VEGF-A is blocked alone, tumours can switch on the
DLL4–Notch signal as an escape route. Blocking both shrank tumours more than blocking either one
in mouse studies, and the regressing vessels let chemotherapy reach more of the tumour
[VERIFIED — Yeom et al. 2020, PubMed] [33][34].

Source(s): design paper [7]; preclinical papers [33][34]
How well is the target validated? Unevenly. VEGF-A blockade is proven in other cancers, but
Open Targets finds no association at all between DLL4 and cholangiocarcinoma or biliary tract
cancer. Its VEGFA association score for cholangiocarcinoma is 0.152, most of it from literature
[VERIFIED — Open Targets association query, 2026-10-17] [18]. No anti-DLL4 drug has ever been
approved. The 44% rate of severe high blood pressure is the expected on-target effect of blocking
these vessel signals [12].
The exact step the next readout must prove. That the tumour shrinkage lasted. Duration of response is the one pre-specified secondary endpoint never reported [3]. It matters more now. Every accelerated approval in second-line biliary cancer rested on “overall response rate and duration of response” [15][16][17]. A long duration is the company’s best argument against the FDA’s request.
The honest scientific risk. The drug shrank tumours and delayed progression, and patients did not live longer. The company blames crossover. Its own crossover-adjusted analysis made the result worse (A.2 evidence below). That contradiction is what the FDA’s 2026-09-22 recommendation addresses [4].
Evidence quality
The seven scores are recorded in asset_evaluation.scores[]. Their mean, 3.7, is the Scientific
rationale domain score from lib/scorecard.mjs.
| Criterion | High (7–10) | Medium (4–6) | Low (1–3) | Where to check | Score | Basis (tagged) [n] · confidence |
|---|---|---|---|---|---|---|
| Target validation | Human genetic evidence, or a clinical precedent with the same target | Strong preclinical data, indirect human data | Preclinical only, or conflicting data | Open Targets, GWAS Catalog, literature | 5 | VEGF-A blockade has clinical precedent in other cancers; DLL4 has no Open Targets link to this disease and no approved drug [VERIFIED — Open Targets 2026-10-17] [18] · Medium |
| Mechanism and target engagement | Proof of mechanism in people (PK and PD, receptor occupancy) | A PD signal with an unclear dose relation | No human PD data | Phase 1 data, publications | 5 | A pharmacokinetic model exists [14]; high blood pressure is a pharmacodynamic sign that VEGF is blocked; no receptor-occupancy or vessel-imaging data published [VERIFIED — PubMed] · Medium |
| Translational biomarkers | A validated PD or selection biomarker with an available assay | An exploratory biomarker | None | Publications, FDA biomarker qualification | 2 | None tested or planned [3] · High |
| Clinical effect against standard of care | Randomised, clinically meaningful effect | Single-arm or small randomised signal | No signal, or a weak one | Registries, publications, congress data | 5 | Randomised gains in response rate and progression-free survival, against paclitaxel rather than FOLFOX; survival hazard ratio 1.05 [4][12] · High |
| Consistency and replication | Replicated across trials or subgroups | One trial | Inconsistent | Trial results | 4 | The Korean Phase 2’s 37.5% response rate fell to 18.0% under randomisation; the colorectal trial failed [7] · Medium |
| Therapeutic window and safety | Wide margin, no class liability | Manageable side effects | Dose-limiting toxicity or a class liability | Toxicology, clinical safety, FAERS, class labels | 3 | 44% grade 3+ high blood pressure, an on-target class effect, against no survival gain [12] · Medium |
| Data transparency and expert view | Peer-reviewed; supportive named experts (A.2b) | Abstracts only; mixed views | Press releases only; sceptical experts | PubMed, congresses, A.2b | 2 | No clinical result is peer-reviewed; every efficacy figure is from a press release; A.2b finds no independent voice (judgement UNKNOWN) [UNVERIFIED — expert view score] · Medium |
The single most important evidence finding, updated. The design paper says the trial “was designed to detect a 23% absolute difference” in response rate with 90% power [7]. The final difference is 12.7 percentage points (18.0% against 5.3%), a little over half the design target [4]. It cleared significance (p=0.0228) because the control arm also did worse than the design assumed. “Significant” and “as large as planned” are different facts. Kept from 5.10.3, which computed 11.8 points from the earlier 17.1% response rate.
The crossover argument does not survive its own check. Kept from 5.10.3 unchanged. 54% of
control patients (31 of 57) crossed over [12]. The standard check, the RPSFT analysis, gave a
survival hazard ratio of 1.13, worse than the unadjusted 1.05 [12]. Removing the effect of
crossover made the drug look worse. The supportive subset the company cites (crossover patients
12.8 months against 6.1 months for non-crossover patients, hazard ratio 0.54, p=0.04) compares
patients who lived long enough to cross over against those who did not. That is survivorship
bias, not evidence. The FDA’s August 2025 draft guidance asks sponsors to treat survival as a
safety endpoint, to rule out harm, and to limit crossover for this very reason
[VERIFIED — FDA draft guidance page] [10].
Endpoints
| Endpoint (full name) | What it measures | Scale / range | Better direction | MCID / note |
|---|---|---|---|---|
| Overall response rate (ORR), the primary endpoint | The share of patients whose tumours shrink enough to count as a complete response (all measurable disease gone) or a partial response (the sum of target-lesion diameters down at least 30%), by RECIST version 1.1 | 0–100% | Higher | No established minimal clinically important difference. Final 18.0% (20/111) against 5.3% (3/57), p=0.0228 [4]. |
| Duration of response (DoR), the figure 2026-10-24 turns on | Among responders, the time from the scan that first confirmed the response to the scan that first confirmed growth | Months | Longer | No established difference. Reference points: 6.9 months in the Korean Phase 2 [7]; the arm’s own 4.7-month median progression-free survival. Not yet reported. |
| Progression-free survival (PFS) | Time from randomisation until the cancer grows or the patient dies | Months | Longer | 4.7 against 2.6 months, hazard ratio 0.44, p<0.0001 [4]. In an open-label trial it is the endpoint most exposed to bias. |
| Overall survival (OS) | Time from randomisation until death from any cause | Months | Longer | 8.9 against 9.4 months, hazard ratio 1.05, p=0.78; RPSFT-adjusted 1.13 [12]. The endpoint the FDA has asked to be shown. |
| Disease control rate (DCR) | The share whose tumours shrank or stayed stable | 0–100% | Higher | Registry secondary endpoint [3]. Not reported. |
| Treatment-emergent adverse events (TEAEs) | Any medical problem arising during treatment, graded 1 (mild) to 5 (fatal) on the CTCAE version 5.0 scale | Counts and percentages by grade | Fewer, milder | Grade 3 means severe. Grade 3+ high blood pressure 44% [12]. |
| EORTC QLQ-C30 (quality of life) | A 30-item patient questionnaire on functioning and symptoms | 0–100 per scale | Higher for functioning, lower for symptoms | In the design paper [7], not in the registry’s outcome list [3], never reported. |
A.2b Named experts
Panel as of. 2026-10-17.
Investigators
CT.gov search_investigators again returned zero rows (condition “biliary tract cancer”,
name “Azad”), and get_trial_details on NCT05506943 carries no investigator block [3]. As in
5.10.3, the investigators below come from the design paper’s author list, each tied to a site on
the trial’s own CT.gov list [3][7].
| Name | Role / affiliation | Trial (NCT) | Conflicts (party, kind, disclosed in, as of) | Conflicts checked (source, date) | Source | Tag |
|---|---|---|---|---|---|---|
| Nilofer Azad | First author of the design paper; presenter of abstract 459O on 2026-10-24; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, a trial site | NCT05506943 | Sponsor: trial investigator and designated presenter, disclosed in Compass’s release of 2026-07-17, as of 2026-07-17. No competitor relationship found. | PubMed get_article_metadata PMID 38861293, 2026-10-17: author list returned, no financial-disclosure section. CT.gov search_investigators, 2026-10-17: zero rows. | [8][7] | VERIFIED — Compass release 2026-07-17 and PubMed 2026-10-17 |
| Milind Javle | Senior author of the design paper; MD Anderson Cancer Center, a trial site and sponsor of the first-line study NCT06548412 | NCT05506943 | Sponsor: trial investigator, disclosed by authorship of the design paper, as of 2024-06-04. No competitor relationship found. | PubMed metadata PMID 38861293, 2026-10-17: no disclosure section. | [7] | VERIFIED — PubMed 2026-10-17 |
| Rachna Shroff | Design-paper author; University of Arizona Cancer Center, a trial site | NCT05506943 | Sponsor: trial investigator, disclosed by authorship, as of 2024-06-04. | PubMed metadata PMID 38861293, 2026-10-17: no disclosure section. | [7] | VERIFIED — PubMed 2026-10-17 |
| Lipika Goyal | Design-paper author; Stanford Cancer Center, a trial site. Also first author of the futibatinib FOENIX-CCA2 paper, a competitor in FGFR2-altered disease. | NCT05506943 | Sponsor: trial investigator, disclosed by authorship, as of 2024-06-04. Competitor: lead author of Taiho’s futibatinib trial, disclosed in the NEJM paper’s byline, as of 2023-01-19. | PubMed metadata PMIDs 38861293 and 36652354, 2026-10-17: no disclosure section in either payload. | [7][23] | VERIFIED — PubMed 2026-10-17 |
| Minori Rosales | Design-paper author at “Compass Therapeutics, 80 Guest Street, Boston”; a sponsor employee | NCT05506943 | Sponsor: employment, disclosed by the affiliation on the paper, as of 2024-06-04. | PubMed metadata PMID 38861293, 2026-10-17: affiliation read directly. | [7] | VERIFIED — PubMed 2026-10-17 |
A limit, kept from 5.10.3. Neither PubMed payload carries a disclosure section, so “no
competitor relationship found” records that a search was made, nothing more
(02-connectors.md § KOL sources). This sweep did find one competitor relationship by reading the
author lists: Lipika Goyal led the futibatinib trial [23]. That row is new.
Independent voices
None found. The literature is still four papers, none of them independent clinical commentary
[7][33][34][14]. No named clinician has commented publicly on the 2026-09-22 FDA position in any source this
sweep reached. The critical coverage is from analysts, not clinicians: Leerink, quoted by
BioSpace, said the FDA “simply recommended a study but did not say it was mandatory” [35]. An
analyst is not a key opinion leader under 01-rules.md rule 40, so that view is not recorded in
this table.
| Name | Affiliation | View (close enough to quote) | As of | Conflicts checked (source, date) | Source | Tag |
|---|
The ESMO discussant of abstract 459O on 2026-10-24 will be the first independent named view. It is on the What to watch list.
Judgement
| Endpoint supported | Basis (one or two sentences) | Tag |
|---|---|---|
UNKNOWN | No independent clinician has commented on this endpoint in any source reached, and no clinical result is peer-reviewed. The FDA’s recommendation is a regulator’s position, recorded in A.4, not an expert view. | UNVERIFIED — judgement |
Dissent
| Name | View (close enough to quote) | Source |
|---|
Empty, correctly: the judgement is UNKNOWN, so there is no claimed support to contest.
A.3 Go / No-Go questions
The next decision is a filing. The filing column marks the questions answered for it. The others are answered too, for the record.
| # | Question | Go to Phase 2 | Go to Phase 3 | Filing | Answer (tagged, at most three points) [n] | Rating | Confidence |
|---|---|---|---|---|---|---|---|
| Target | |||||||
| T1 | Is proof of mechanism or principle established in people (target engagement, PD) with this candidate? | ● | ● | High blood pressure shows VEGF blockade; tumours shrank; no direct DLL4 engagement data [VERIFIED — Compass 2026-04-27] [12][14] | amber | M | |
| T2 | If the early population differs from the intended population, how is the evidence translated? | ● | ● | The Korean Phase 2 (37.5% response) did not translate to the US randomised trial (18.0%) [4][7] | amber | M | |
| T3 | Is there a rationale for combinations, and is it pursued? | ● | ● | ● | Paclitaxel synergy in mice [33]; a first-line combination with gemcitabine, cisplatin and durvalumab is under way (NCT06548412) [3] | green | M |
| Dose and drug | |||||||
| D1 | Is the exposure–response relationship and the therapeutic window defined for the intended regimen and route? | ● | ● | ● | No exposure–response model [14]; 44% grade 3+ high blood pressure at 10 mg/kg [12] | red | M |
| D2 | Is the dose and regimen compatible with the clinical and non-clinical safety data? | ● | ● | ● | No dose-limiting toxicity up to 17.5 mg/kg in Phase 1 [7]; the combination’s blood-pressure rate is high [12] | amber | M |
| D3 | Does the formulation deliver therapeutic exposure, and is it commercially viable (the final formulation for Phase 3)? | ● | ● | ● | Intravenous antibody; validation batches under way at unnamed contract sites [1] | amber | L |
| D4 | Are intrinsic and extrinsic factors (organ impairment, drug interactions, ethnicity, body weight) characterised? | ● | ● | Body weight only [14]; no organ-impairment or interaction studies | amber | M | |
| Patient and design | |||||||
| P1 | Are the design and endpoints accepted by the FDA and EMA, clinically meaningful, competitive, and relevant for HTA bodies (B.3)? | ● | ● | ● | No. The FDA recommended a survival trial before a filing [VERIFIED — 8-K exhibit 99.1] [4]; the comparator is not FOLFOX [3][5] | red | H |
| P2 | What is the rationale for the population; is a selection biomarker validated, with a companion diagnostic plan? | ● | ● | ● | All comers is a strong commercial rationale; no selection marker [3] | amber | M |
| P3 | What is the probability of success of the next trial (effect-size assumptions, statistical power, trial simulation or assurance)? | ● | ● | A survival trial is not designed. The randomised data (hazard ratio 1.05) give no sign it would succeed [12] | red | L | |
| P4 | Has proof of concept with a positive benefit–risk balance been shown in the intended population? | ● | ● | Concept yes (response rate, progression-free survival); positive benefit–risk no, on the FDA’s reading [4][12] | red | M | |
| Benefit–risk | |||||||
| R1 | Is the safety database adequate for the indication (exposure, duration); are class effects or a REMS expected? | ● | ● | 111 treated in the tovecimig arm plus 31 crossover patients; the blood-pressure class effect is known [12] | amber | M | |
| R2 | Is the overall benefit–risk balance favourable against the current standard of care? | ● | ● | Not shown: no survival gain over paclitaxel and no comparison with FOLFOX [12][5] | red | M |
The Clinical data and design domain is a direct score of 4 (amber). Basis: P1, P3, P4, R2 and D1 are red; T3 is green; the rest amber. The randomised design and a met primary endpoint keep it above the red band. · confidence Medium
A.4 Regulatory pathway
| Topic | Questions | Answer (tagged) [n] | Where to look |
|---|---|---|---|
| Pathway | Which route: NDA or BLA, 505(b)(2), EU centralised MAA, conditional authorisation or accelerated approval? Is a confirmatory trial required, and is it feasible? | A BLA for accelerated approval on response rate and progression-free survival was the plan [36]. On 2026-09-22 the FDA “recommended that Compass conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application” [VERIFIED — 8-K exhibit 99.1] [4]. Compass “does not believe that a new trial is warranted” and is preparing a BLA anyway [4]. A filing can be submitted against the FDA’s advice; the FDA can refuse to file it or reject it. Leerink estimated a new trial would mean about a three-year delay [WEB ESTIMATE — BioSpace, 2026-09-22] [35]. | FDA guidance [10] |
| Designations | Breakthrough Therapy, Fast Track, RMAT, Orphan Drug, priority review voucher (FDA); PRIME, orphan (EMA); Sakigake, orphan (PMDA): granted, or realistic? | Fast Track (2024-04-25) and Orphan Drug (announced by 2026-04-08) are held [11][13]. No Breakthrough Therapy designation. No EU or Japanese designation found as of 2026-10-17. | FDA registers |
| Agency alignment | End-of-Phase-2 meeting, scientific advice, SPA, parallel EMA and HTA advice: was the pivotal design agreed? | No Special Protocol Assessment is disclosed. The design allowed crossover [7]. The FDA’s 2026-09-22 position followed a meeting the company called “discussions last month” [WEB ESTIMATE — BioSpace quoting the release, 2026-09-22] [35]. | Company disclosures |
| Precedent | Have drugs been approved on the same endpoint and design in this indication? Any recent rejections in the class? | Three accelerated approvals in second-line biliary cancer rest on “overall response rate and duration of response”: zanidatamab (HER2), pemigatinib (FGFR2) and futibatinib (FGFR2) [VERIFIED — DailyMed labels] [15][16][17]. All three came from single-arm trials in marker-selected patients. Tovecimig is different: it has a randomised survival result, and it points the wrong way. The FDA’s draft guidance treats that as a harm signal to rule out [10]. | Drugs@FDA, DailyMed |
| Review risk | Likelihood of an advisory committee; safety signals; manufacturing inspection; co-approval of a diagnostic; post-marketing requirements | If a BLA is filed without a survival trial, an advisory committee is likely [UNVERIFIED — judgement]. No diagnostic is needed. The contract manufacturing sites would face their first pre-approval inspection (M.3). | AdComm materials |
The Regulatory pathway domain is a direct score of 3 (red). Basis: the agency has recommended a survival trial before any filing; the designations held do not lower the evidence bar. · confidence High
Designations.
- Fast Track, granted 2024-04-25. It grants more frequent FDA meetings and a rolling review; it
does not lower the evidence bar
[VERIFIED — BPIQ note 4/25/24; OncLive 2024-04-25][13]. - Orphan Drug designation for biliary tract cancer. It grants seven years of US exclusivity
for this disease from approval, tax credits and a fee waiver
[VERIFIED — CancerNetwork, 2026-04-08][11]. Named correction: the 5.10.3 version dated it “around 2026-05-05”, the date of the BPIQ note; press coverage shows it was announced by 2026-04-08. - No Breakthrough Therapy designation. None appears in the note history or the press feed
[UNVERIFIED — absence of evidence].
A.5 Clinical operations

Source(s): CT.gov [3]; design paper [7]; Compass releases [4][12]; competitor trial dates [5][20][21][22]
Milestone dates. Enrolment completed 2024-08-06 [VERIFIED — BPIQ note]. The primary-endpoint
readout came on 2025-04-01 and the survival readout on 2026-04-27 [12]. The registry’s
primary_completion_date moved from 2026-12-01 (read 2026-08-19) to 2027-08-31 (read
2026-10-17) [3]. The registry does not say why. It is consistent with longer survival follow-up,
but that reading is [UNVERIFIED].
Trials
| Trial | Sponsor / whose drug | Design (arms, blinding, n) | Population | Status / key result | Link |
|---|---|---|---|---|---|
| COMPANION-002 (NCT05506943), pivotal | Compass; its own drug | Phase 2/3, multicentre, open-label, randomised 2:1, tovecimig + paclitaxel against paclitaxel; n=168 at 34 US sites; crossover allowed at progression | Adults with advanced biliary tract cancer after one gemcitabine-platinum regimen, performance status 0–1, not eligible for a targeted drug | Active, not recruiting. Response rate 18.0% against 5.3% (p=0.0228); progression-free survival 4.7 against 2.6 months (hazard ratio 0.44); survival 8.9 against 9.4 months (hazard ratio 1.05). Duration of response unreported. | NCT05506943 [4][12] |
| NCT04492033, the Korean study COMPANION-002 was built on | Handok; ABL Bio’s drug | Phase 1b/2a, open-label, single-arm; n=41 | Advanced biliary tract cancer after one or two therapies | Terminated. Phase 2 cohort (n=24): response rate 37.5%, median duration 6.9 months, progression-free survival 9.4 months | NCT04492033 [7] |
| NCT03292783, first in human | ABL Bio; its own drug | Phase 1 dose escalation, nine levels, 0.3–17.5 mg/kg; n=45 | Heavily pretreated solid tumours | Completed. No dose-limiting toxicity; high blood pressure 37.8% | [7] |
| COMPANION-003 (NCT05513742) | Compass; its own drug | Phase 2, single-arm; n=49 | Colorectal cancer after two or three regimens | Completed; did not advance. Response rate 5% (2/41) | NCT05513742 |
| NCT06548412, first line | MD Anderson; Compass’s drug | Phase 1/2, open-label; n=50; with gemcitabine, cisplatin and durvalumab | Untreated advanced biliary tract cancer | Recruiting; primary completion 2027-05-01 | NCT06548412 |
| NCT07662031 and NCT07392957 | Washington University; Compass’s drugs | Phase 2 (n=25, colorectal) and Phase 1b/2 (n=54, glioblastoma) | Other cancers | Investigator-sponsored; not this program | NCT07392957 |
| ABC-06, competitor precedent | UK academic group; generic chemotherapy | Phase 3, open-label, randomised 1:1, FOLFOX + symptom care against symptom care; n=162 | Second-line biliary tract cancer after cisplatin and gemcitabine | Survival 6.2 against 5.3 months (hazard ratio 0.69, p=0.031); grade 3–5 events 69% against 52% | [5] |
Pivotal programme
| Trial | Setting | Design / comparator | Key result [n] | Use |
|---|---|---|---|---|
| COMPANION-002 | Second line, all comers | Randomised against paclitaxel, open-label, crossover allowed | Response rate and progression-free survival met; survival not met [4][12] | Intended for US accelerated approval; the FDA recommends a survival trial first [4] |
Effect by trial
Not applicable as a cross-trial comparison — one randomised trial so far. The table records that trial’s own effects for reference.
| Trial | Endpoint | Effect (hazard ratio or other, named) | 95% confidence interval | n | Source |
|---|---|---|---|---|---|
| COMPANION-002 | Progression-free survival | Hazard ratio 0.44 | Not disclosed in the sources read | 168 | [4] |
| COMPANION-002 | Overall survival | Hazard ratio 1.05 (unadjusted); 1.13 (RPSFT-adjusted) | Not disclosed in the sources read | 168 | [12] |
Operational parameters
| Parameter | High (7–10) | Medium (4–6) | Low (1–3) | Where to check | Score | Basis (tagged) [n] · confidence |
|---|---|---|---|---|---|---|
| Recruitment feasibility | Sites and countries adequate for the disease’s prevalence; enrolment on or ahead of benchmark | Adequate, with competing trials for the same patients | Rare population, few sites, enrolment delays | ClinicalTrials.gov, EU CTIS | 8 | 168 patients at 34 US academic sites, enrolment complete 2024-08-06 [3] · High |
| Endpoint acceptance | Regulatory precedent in FDA or EMA guidance | Novel endpoint with documented agency agreement | Unvalidated surrogate | FDA and EMA guidance, EPARs | 3 | Response rate has precedent in this disease [15][16][17], but the FDA has asked for survival here [4] · High |
| Design robustness | Randomised, controlled, agreed with the agencies (SPA) | Adaptive or seamless, with a pre-specified interim | Single-arm without a robust external control | Protocol, SPA, scientific advice | 5 | Randomised and controlled, but open-label, 2:1, crossover allowed, no SPA [3][7] · High |
| Execution track record | Sponsor met its prior milestones | Minor delays | Repeated delays, CRO or site problems | Company history, 8-K filings, ../company.md C.1a | 4 | Survival data a month late; BLA guidance missed; CTX-471 start missed five dates (../company.md C.1a) · High |
Resourcing sufficiency. For the 2026-10-24 presentation, yes: the data are locked and the slot
is booked. For what comes next, not clearly. The company held $179.9M at 2026-06-30 and guides to
a runway “into 2028” (../company.md C.3). That guidance predates the FDA’s
request for a survival trial. A new randomised survival trial in this disease would take years
(B.4c). The company has not said whether it will run one or how it would pay for it. Its
39-person staff and missed guidance (C.1a) argue against a fast start.
A.6 Probability of success
Base rate. baseRate in lib/success-rates.mjs was run with phase phase3, area oncology
and modality bispecific. The phase is phase3 because COMPANION-002 is the registrational Phase
2/3 trial and the next step is a filing. BIO 2021 has no bispecific row, so the lookup falls back to
the oncology row.
Base rate: 47.7% to the next phase (Phase III to NDA/BLA) · 43.9% to approval · source
BIO 2021, Figure 2, p. 7 · fallback level: area (oncology) · Wong 2019: not broken out for Phase 3
to the next phase; 35.5% for Phase 3 to approval [WEB ESTIMATE — BIO/Informa/QLS 2021]
Adjustments
| Factor | Direction (up / down) | Evidence [n] | Tag |
|---|---|---|---|
| Biomarker-selected population | down | None; all comers. Programs with a selection biomarker approve more often; this one has none [3] | VERIFIED — CT.gov |
| Human genetic support for the target | down | No Open Targets association between DLL4 and the disease; VEGFA 0.152 [18] | VERIFIED — Open Targets 2026-10-17 |
| Rare disease or orphan designation | up | Orphan Drug and Fast Track designations; a clear unmet need [11][13] | VERIFIED — designation coverage |
| Randomised Phase 2 with a meaningful effect | up | Randomised gains in response rate and progression-free survival (hazard ratio 0.44) [4] | VERIFIED — 8-K exhibit 99.1 |
| First-in-class, novel endpoint, or prior failures in the class | down | No anti-DLL4 drug approved; survival hazard ratio 1.05, 1.13 after crossover adjustment [12] | VERIFIED — Compass 2026-04-27 |
| Other, named: the FDA recommended a survival trial before a BLA | down | The regulator’s own position on these data, 2026-09-22 [4] | VERIFIED — 8-K exhibit 99.1 |
Result
| Low | Base | High | Basis | |
|---|---|---|---|---|
| To the next phase | 30% | 45% | 60% | The next phase is a filing. The company says it will file; the FDA’s advice, the cost and the refuse-to-file risk pull the figure down from 47.7% [UNVERIFIED — modelled] |
| To approval | 5% | 12% | 22% | Approval on the current data needs the FDA to reverse its advice; approval after a new survival trial needs that trial to succeed where the current one showed no trend [UNVERIFIED — modelled] |
A.7 Modality
- Modality:
bispecific. A full IgG antibody against VEGF-A with two single-chain fragments against DLL4 fused to its ends (“IgG with 2× C-terminal scFv”) [7][19]. - Manufacturing is assessed in M below. Its CMC score feeds the Operations and CMC domain.
M. Manufacturing (CMC)
The full form applies: the program sits at its filing decision after a Phase 2/3 pivotal trial. The manufacturing tier of the sweep was run (section 0). CMC means chemistry, manufacturing and controls: how the drug is made and quality-checked.
M.1 Product and process
| Element | Describe | This asset [n] |
|---|---|---|
| Molecule or construct | For an antibody: isotype and expression system. For a conjugate: linker chemistry, payload class, conjugation site, DAR and its distribution. For a gene therapy: vector or capsid. For an RNA drug: the lipid nanoparticle. For a radioligand: the isotope | A humanised IgG against VEGF-A with two anti-DLL4 single-chain fragments fused to the heavy-chain ends [7]. Isotype and cell line: no public record as of 2026-10-17. |
| Drug substance steps | Upstream (growing the cells), downstream (purifying the product), payload and linker synthesis, conjugation, purification; in-house or CDMO for each step | All at unnamed contract manufacturers. Compass owns no plant [VERIFIED — Form 10-K for 2025] [2] |
| Drug product | Formulation (liquid or freeze-dried), presentation, device, stability and shelf life, refrigerated transport (cold chain) | Intravenous infusion; formulation and shelf life not disclosed |
| Analytics | The critical quality attributes (such as DAR, free payload, aggregates, potency assay, vector genomes) and the release and characterisation methods | Not disclosed. A dual-binding potency assay would be expected for a bispecific [UNVERIFIED — judgement] |
| Companion diagnostic | The assay, its partner, and the timing of its co-approval (A.4) | Not applicable — no biomarker |
M.2 Challenges by process step
| Process step | Typical challenges | Status and readiness (tagged) [n] | Rating |
|---|---|---|---|
| Drug substance (biologic) | Titre, cell-line stability, glycosylation, scale-up | Clinical supply delivered through a 168-patient trial; commercial-scale status undisclosed [UNVERIFIED] | amber |
| Payload and linker | HPAPI synthesis and containment, supply chain, impurities | Not applicable — not a conjugate | not applicable |
| Conjugation or assembly | DAR control and distribution, unconjugated antibody, aggregation, yield | Not applicable as conjugation. Fused single-chain fragments can raise aggregation risk [UNVERIFIED — class judgement] | amber |
| Analytics and comparability | Potency assay, CQA definition, comparability after a process change or a site transfer | Not disclosed [UNVERIFIED] | amber |
| Drug product and stability | Formulation, freeze-drying, shelf life, cold chain | Not disclosed [UNVERIFIED] | amber |
| Scale-up and tech transfer | Commercial-scale process, transfer to several sites, validation (PPQ) | The 10-Q lists “registration and validation batches” among manufacturing costs and $7.5M of accrued manufacturing expense, mostly tovecimig [VERIFIED — Form 10-Q filed 2026-08-06] [1] | amber |
| Capacity and supply | Capacity against the demand forecast, CDMO dependency, dual sourcing, shortages or over-capacity | Fully dependent on unnamed CDMOs; dual sourcing not disclosed [2] | amber |
| Cost of goods | COGS against the price corridor (B.3); the effect of dose (mg per kg) and yield | A 10 mg/kg dose every two weeks is a lot of antibody per patient; no cost disclosed [UNVERIFIED] | amber |
| Regulatory CMC | Pre-approval inspections, Form 483 observations, CRLs, post-approval changes | No CRL, warning letter or inspection record found for the sponsor [31]; the sites are unnamed, so site records could not be searched | amber |
M.3 Regulatory CMC track record
| Item | What to record | Where to find it | Finding (tagged) [n] |
|---|---|---|---|
| CMC-related CRLs | Date, product, reason, time to resolution | openFDA’s complete response letter data, company press releases | No public record as of 2026-10-17 (openFDA CRL API, NOT_FOUND for Compass, ABL and tovecimig) [31] |
| Inspections | Form 483 observations and warning letters at the drug substance, drug product and CDMO sites | FDA warning letters, the FDA inspection dashboard | No public record as of 2026-10-17 for the sponsor. CDMO sites unnamed, so not searchable |
| Review documents | The product quality review and post-marketing CMC commitments (FDA); the quality section of the EPAR (EMA) | Drugs@FDA, EMA EPARs | Not applicable — no application filed |
| Supply events | Shortages, recalls, allocation | FDA drug shortages, company filings | No public record as of 2026-10-17 (openFDA shortages API) [32] |
M.4 Network and capacity
The company-level facts are in ../company.md C.1a: no owned plants, unnamed
contract manufacturers.
| Topic | Finding (tagged) [n] |
|---|---|
| Sites for each step (own or CDMO), regions, planned investments and their timing against demand | All contract sites, unnamed; validation batches were being made in 2026 for a planned BLA [1]. A survival trial would delay the commercial need by years [UNVERIFIED — judgement] |
| Geopolitical and tariff exposure; single points of failure | Unknown, because the sites are unnamed. The originator is Korean; whether any drug substance is made in Asia is not disclosed [UNVERIFIED] |
| Capacity strategy: risk-adjusted or maximum-demand planning; take-or-pay contracts | Not disclosed. Validation-batch spending ahead of an FDA position that now points to delay creates a write-down risk [UNVERIFIED — judgement] |
M.5 Modality questions
| Modality | Key CMC and technology questions | Answer for this asset (tagged) [n] |
|---|---|---|
| Small molecule | Solubility and bioavailability, polymorphs, route of synthesis at scale, nitrosamine risk | — |
| Antibody, protein or bispecific | Titre and yield, stability, high-concentration subcutaneous formulation, immunogenicity | Titre, stability and immunogenicity: no public data as of 2026-10-17. Intravenous only; no subcutaneous form planned. A 10 mg/kg dose makes yield matter for cost [UNVERIFIED] |
| Antibody-drug conjugate | Linker and payload stability, DAR control, payload toxicity, payload supply | — |
| Cell therapy | Vein-to-vein time, manufacturing success rate, capacity, cost of goods, treatment-centre network | — |
| Gene therapy | Vector yield and potency assay, dose-related toxicity, durability, redosing, cost of goods | — |
| RNA or oligonucleotide | Delivery (liver against other tissues), dosing interval, class safety (platelets, kidney) | — |
| Radioligand or other | Isotope supply, logistics and half-life, site infrastructure | — |
M.6 CMC score and top risks
| Criterion | High (7–10) | Medium (4–6) | Low (1–3) | Score | Basis (tagged) [n] · confidence |
|---|---|---|---|---|---|
| Process robustness and CQAs | Validated commercial process; well-defined CQAs | Process changes pending; comparability needed | Quality problems recognised late | 5 | Validation batches in progress; nothing published on quality attributes [1] · Low |
| Regulatory CMC record | No CMC-related CRL or Form 483 issue | Minor observations, resolved | A CMC CRL, a warning letter or a refusal | 6 | No record found, but no application has been inspected yet [31] · Low |
| Capacity and supply | Capacity matched to demand; dual sourcing | Constrained, or a single site | Shortages, or a major over-capacity write-down | 5 | Unnamed CDMOs; no dual sourcing disclosed [2] · Low |
| Cost of goods | Compatible with the price corridor | Margin pressure | COGS threatens viability | 5 | High dose per patient; orphan pricing likely covers it [UNVERIFIED] · Low |
CMC score: 5.3 (mean of the four, from lib/scorecard.mjs)
Top-3 CMC risks. 1. Contract sites unnamed, so no inspection history can be checked [2].
2. Validation spending ahead of a delayed filing could be written off [1]. 3. Bispecific
fusion formats can aggregate; no stability data are public [UNVERIFIED].
B. Commercial value
B.1 Treatment today and competitors
Treatment algorithm. First line is gemcitabine and cisplatin, now usually with durvalumab
(TOPAZ-1) [VERIFIED — Imfinzi label] [27] or pembrolizumab [UNVERIFIED — not read this sweep]. At progression the path forks by tumour test:
- About 13% of intrahepatic cholangiocarcinomas carry an IDH1 mutation and go to ivosidenib
[VERIFIED — ClarIDHy abstract][24][26]. - FGFR2 fusions go to pemigatinib or futibatinib, both accelerated approvals [16][17].
- HER2-positive (IHC 3+) disease goes to zanidatamab, an accelerated approval [15].
- Everyone else gets chemotherapy: FOLFOX on the strength of ABC-06 [5], or liposomal
irinotecan with 5-FU on the strength of NIFTY [20]. The share without a targetable alteration is
about 70–80%
[WEB ESTIMATE — Frontiers in Oncology 2026 review and DelveInsight, via the 2026-08-19 sweep; URL not recorded].
Where tovecimig would fit. In that last group, added to paclitaxel. COMPANION-002 excludes patients eligible for a targeted drug [3].
Competitors
| Competitor (drug, company) | Stage | Key data [n] | Note (indirect comparison) |
|---|---|---|---|
| FOLFOX (generic) | Standard of care, off-label | ABC-06: survival 6.2 against 5.3 months, hazard ratio 0.69; grade 3–5 events 69% [5] | Indirect. Unlike COMPANION-002, ABC-06 shows a survival benefit. |
| Liposomal irinotecan + 5-FU/LV (nal-IRI) | Off-label; Phase 2b evidence | NIFTY (Korea): progression-free survival 4.2 against 1.7 months, hazard ratio 0.61 [20] | Indirect; Korean population; a German trial (NALIRICC) was not read this sweep. |
| Zanidatamab (Ziihera), Jazz | Approved (accelerated), HER2-positive only | Response rate 41.3%; grade 3 treatment-related events 18% [21][15] | Indirect; single-arm; marker-selected. |
| Pemigatinib (Pemazyre), Incyte | Approved (accelerated), FGFR2 only | Response rate 35.5%; grade 3+ events 64% [22][16] | Indirect; single-arm; marker-selected. |
| Futibatinib (Lytgobi), Taiho | Approved (accelerated), FGFR2 only | Response rate 42%; median duration of response 9.7 months [23][17] | Indirect; single-arm; marker-selected. |
| Ivosidenib (Tibsovo), Servier | Approved, IDH1 only | Progression-free survival 2.7 against 1.4 months on placebo, hazard ratio 0.37 [24][26] | Indirect; marker-selected; randomised against placebo. |
Competitive position
| Metric | High value (7–10) | Medium value (4–6) | Low value (1–3) | Where to check | Score | Basis (tagged) [n] · confidence |
|---|---|---|---|---|---|---|
| Mechanism differentiation | First-in-class, or clearly best-in-class | Next-generation improvement | Me-too | Publications, the competitor list above | 7 | First DLL4 × VEGF-A bispecific in a pivotal trial; no anti-angiogenic drug approved in this disease [19] · Medium |
| Timing against competitors | More than 12 months ahead of the nearest competitor | Within 6 to 12 months | Lagging by more than 12 months | ClinicalTrials.gov | 5 | No other randomised all-comer drug is near filing, but a survival trial would push tovecimig back about three years [35] · Medium |
| Clinical data against competitors | Superior efficacy, safety or convenience (B.1a) | Comparable | Inferior | Publications, congress data | 4 | Better response rate than FOLFOX, no survival gain, more severe high blood pressure (B.1a) · Medium |
| IP and exclusivity | 10 years or more after launch (composition of matter) | 5 to 10 years, or method of use only | Under 5 years, or pending only | Orange Book, Purple Book, patent databases | 6 | Two licensed patent families, 2 US patents, expiring “starting in 2033, subject to possible extension” [VERIFIED — Form 10-K for 2025] [2]; a new biologic gets 12 years of US exclusivity from licensure and the orphan grant 7 years [UNVERIFIED — statutory default] · Medium |
Named correction. The 5.10.3 version said no patent estate could be found. The 10-K describes it. Whether the 2033 patents cover the molecule itself is not stated.
Strategic insight. In oncology, first movers with novel mechanisms have shown roughly 3.2×
higher peak sales and 1.8× higher development risk than fast followers [UNVERIFIED — illustrative] (07-benchmarks.md § Rules of thumb). Tovecimig now carries the second half of
that line. It wins only if the field accepts tumour control without a survival gain. The single
fact the case rests on is unchanged from 5.10.3 but has now been tested: whether the FDA accepts
response rate and progression-free survival without survival. On 2026-09-22 the answer was no [4].
B.1a Efficacy against side effects
Every comparison here is indirect (01-rules.md rule 17). Patients, lines of therapy, follow-up
and side-effect definitions differ across these trials. Three of the four points are single-arm or
marker-selected. Tovecimig’s point is early data and uses a lower bound for harm.

Source(s): COMPANION-002 [4][12] · ABC-06 [5] · HERIZON-BTC-01 [21] · FIGHT-202 [22]. Indirect comparison across trials (rule 17). Scaling: x = response rate ÷ 50%; y = 1 − (grade 3+ rate ÷ 100%).
| Indication | Regimen (trial) | Efficacy (endpoint, value) | Grade 3 or higher adverse events (%) | Adverse event definition (any cause, treatment-emergent or treatment-related) | Source |
|---|---|---|---|---|---|
| 2L BTC, all comers | Tovecimig + paclitaxel (COMPANION-002) | Response rate 18.0% | At least 44% (grade 3+ high blood pressure alone; the overall rate is not published) | Treatment-emergent, by event | [4][12] |
| 2L BTC, all comers | Paclitaxel (COMPANION-002 control) | Response rate 5.3% | Not published | — | [4] |
| 2L BTC, all comers | FOLFOX + symptom care (ABC-06) | Survival 6.2 months; response rate about 5% [WEB ESTIMATE — via the 2026-08-19 sweep] | 69% (grade 3–5) | Any cause | [5] |
| 2L BTC, all comers | nal-IRI + 5-FU/LV (NIFTY) | Progression-free survival 4.2 months | Not in the abstract read | — | [20] |
| 2L BTC, HER2-positive | Zanidatamab (HERIZON-BTC-01) | Response rate 41.3% | 18% (grade 3) | Treatment-related | [21] |
| 2L CCA, FGFR2 fusion | Pemigatinib (FIGHT-202) | Response rate 35.5% | 64% | Any cause | [22] |
| 2L iCCA, FGFR2 fusion | Futibatinib (FOENIX-CCA2) | Response rate 42% | Hyperphosphataemia 30% (grade 3, treatment-related); overall rate not in the abstract | Treatment-related | [23] |
| 2L CCA, IDH1 | Ivosidenib (ClarIDHy) | Progression-free survival 2.7 months | Ascites 7% the most common; overall rate not in the abstract | Any cause | [24] |
B.2 Addressable market
Launch market: the United States only. Compass holds rights outside South Korea and China but
has described no European or Japanese launch [2]. Orphan market, so the guide’s 100,000-patient
threshold does not apply (01-rules.md rule 9).
| Component | How it is estimated | Assessment guide | This asset (tagged) | Source [n] |
|---|---|---|---|---|
| Drug-treated patients | Prevalence or incidence × diagnosis rate × treatment rate × eligible share | More than 100,000 (US, EU5, Japan) is a premium threshold for a common disease; judge an orphan market relative to its area | About 2,080–3,190 US patients a year (funnel in B.4a). Two incidence figures disagree and are used as the two ends, not averaged: 18,600 (American Cancer Society, quoted in the design paper) and 12,130 (a SEER-based estimate). Kept from 5.10.3. | ACS [VERIFIED — via the design paper] [7]; SEER [WEB ESTIMATE — epidemiology papers, via the 2026-08-19 sweep] |
| Exclusivity | Patent term + extensions (PTE, SPC) + regulatory, orphan or paediatric exclusivity | Years of exclusivity after launch; the generic or biosimilar entry date | Patents from 2033 plus possible extension [2]; 12 years of biologic exclusivity from approval [UNVERIFIED — statutory default]; 7 years orphan [11]. Likely 10 years or more from a launch near 2029–2030 | [2][11] |
| Reimbursement precedent | Approvals and payer decisions in two or more major markets | Positive NICE or CADTH guidance for a drug like this one | None for tovecimig. Nearest analogue: NICE recommended ivosidenib only with a confidential discount [37] | [37] |
| Price corridor | Comparator and analogue prices; a value-based price | Worked out in B.3 | Modelled at $20,000–30,000 a month, orphan-oncology range [UNVERIFIED — assumption] | B.3 |
| Patient and system impact | Hospitalisations, caregiver burden, HRQoL | The size of the effect and the evidence for it | Not shown; blood-pressure monitoring adds burden; no quality-of-life data [12][7] | [12][7] |
B.3 Payers and price
The United States is assessed. The EU, Germany, the UK and Japan are not in the launch plan, so
their rows say Not applicable and the payer tier was not run.
Per market
| Market | In scope? | Expected outcome | Price implication | Key risk | Source [n] |
|---|---|---|---|---|---|
| United States: ICER benchmark; Medicare negotiation exposure (IRA timing, orphan exclusion) | Always | Coverage likely if approved, as for other orphan cancer drugs; no ICER review of any biliary drug found | Orphan-level pricing; a biologic is not negotiable until 11 years after approval, and the widened 2025 orphan exclusion would shelter an orphan-only label [WEB ESTIMATE — Milliman, 2026] | No survival gain to justify a price above generic chemotherapy | [29][30][28] |
| EU joint clinical assessment (JCA) | No | Not applicable — no EU launch plan | — | — | [2] |
| Germany: G-BA and IQWiG (AMNOG) | No | Not applicable — no EU launch plan | — | — | [2] |
| UK: NICE | No | Not applicable — no UK launch plan | — | — | [2] |
| Japan: Chuikyo | No | Not applicable — no Japan launch plan | — | — | [2] |
Questions
| Question | Answer (tagged) [n] |
|---|---|
| Comparator: does the pivotal trial compare against what payers require (the G-BA’s appropriate comparator, the NICE scope, the JCA’s PICO, the US standard of care)? If not, is a credible bridge planned, such as an indirect comparison or an external control? | No. The comparator is paclitaxel; the US standard of care is FOLFOX [3][5]. No bridge disclosed. |
| Endpoints and certainty: patient-relevant endpoints (mortality, morbidity, quality of life, safety) or surrogates? Will payers discount the design (single-arm, crossover, immature data)? | Surrogates (response rate, progression-free survival); survival flat; crossover confounds it [4][12]. |
| Supplementary evidence: quality-of-life data (EQ-5D), early payer advice (EU joint scientific consultation, G-BA, NICE), real-world or natural-history data, an early cost-effectiveness model? | None reported. QLQ-C30 was planned but never reported [7]. |
| Value against price: a realistic G-BA added-benefit category; cost per QALY against the NICE threshold; the ICER price benchmark. Do they support the target price against the comparator? | With no survival or quality-of-life gain, the QALY gain is close to zero, so no cost-per-QALY threshold supports a premium [UNVERIFIED — judgement]. |
| Access conditions: likely restriction to sub-populations, managed access or confidential discounts, post-launch data obligations? | A confirmatory survival trial would be a condition of any accelerated approval [10]. |
| US comparator annual cost (list price), the ICER benchmark, and the Medicare negotiation timing for this drug (small molecule 7 years, biologic 11 years after approval; orphan exclusion) | FOLFOX is generic. No ICER benchmark exists. As a biologic, 11 years; the widened orphan exclusion may apply [29]. |
Market access criteria
| Criterion | High (7–10) | Medium (4–6) | Low (1–3) | Score | Basis (tagged) [n] · confidence |
|---|---|---|---|---|---|
| Comparator alignment | Randomised trial against the payers’ comparator | Robust indirect comparison | Placebo or single-arm only | 4 | Randomised, but against paclitaxel, not FOLFOX [3] · High |
| Endpoints and certainty | Hard endpoint, mature, randomised | Surrogate, immature | Unvalidated surrogate, single-arm | 3 | Surrogates only; survival flat [4][12] · High |
| Supplementary evidence plan | Quality of life (EQ-5D), payer advice, real-world evidence, a cost-effectiveness model | Partial | Not addressed | 2 | Nothing reported [7] · Medium |
| Value for money at the target price | Within the NICE threshold, or at or below the ICER benchmark | Needs a discount | Far above the thresholds | 3 | No QALY gain against a generic [UNVERIFIED — judgement] · Medium |
| Payer precedent | Positive, with a premium price | Restricted or mixed | Rejected, or priced at the comparator | 4 | Marker-selected biliary drugs are reimbursed; ivosidenib only with a discount in England [37] · Medium |
Market Access Score: 3.2 (mean of the five, from lib/scorecard.mjs)
Payer decisions
| Market | Indication / evidence | Outcome (body’s own words, date) | Main reason | Source [n] |
|---|---|---|---|---|
| England (NICE TA948) | Ivosidenib, IDH1-mutant cholangiocarcinoma after one or more treatments | Recommended “only if the company provides it according to the commercial arrangement” [WEB ESTIMATE — search summary of the NICE page, 2026-10-17] | Cost-effectiveness needed a discount | [37] |
B.4 Valuation and financing
B.4a Peak sales
Built bottom-up, US only, conditional on approval, gross of ABL Bio’s royalty. Kept from 5.10.3. Launch now assumed near 2029–2030 rather than 2028, because a survival trial or a contested filing both push it back. The uptake shape is in Visual 4.
Patient funnel: 12,130–18,600 US diagnoses a year × ~68% advanced × ~70% treated in first line ×
~45% fit for second line × ~80% without a targetable alteration = 2,080–3,190 patients
[UNVERIFIED — assumptions, kept from 5.10.3]. Price: $20,000–30,000 a month × about 5 months of
treatment = $100,000–150,000 a patient [UNVERIFIED — assumption].
| Scenario | Assumptions (patients × price × share × duration) | Estimate (USD/year at peak) | Basis / tag |
|---|---|---|---|
| Low | 2,000 × $100,000 × 25% | $50M | Narrow approval; most oncologists stay with FOLFOX [UNVERIFIED — modelled] |
| Base | 2,600 × $125,000 × 45% | $146M | Approval; adoption in about half of eligible patients [UNVERIFIED — modelled] |
| High | 3,200 × $150,000 × 65% | $312M | Approval plus a durable response that reframes survival, plus first-line pull-through [UNVERIFIED — modelled] |
The weakest input is the price, then penetration. Kept from 5.10.3. No tovecimig price exists and no all-comer add-on has launched in this disease. Patient count is the strongest input.
Rejected input, with its audit trail. The 5.10.3 sweep found no published peak-sales figure.
This sweep found one: William Blair’s $1.46 billion worldwide in previously treated biliary
cancer, resting on “about 15,000 patients annually in the United States likely eligible”
[WEB ESTIMATE — William Blair initiation, as summarised by search coverage; pre-dates the 2025 readout] [38]. It is not used. 15,000 eligible second-line patients is close to the total number
of US biliary cancer diagnoses (12,130–18,600), before any loss to early-stage disease, death
before second line or targeted therapy. It also predates the April 2026 survival result and the
FDA’s position. LifeSci Capital’s “around $1.4 billion” US opportunity is set aside for the same
reasons.
B.4b Value
| Scenario | eNPV (USD) | Assumptions (discount rate, costs, royalties and milestones, loss of exclusivity, probability of success) | Tag |
|---|---|---|---|
| Low | −$60M | Value at approval $90M (low peak × 2 × 0.9) × 5% approval odds, less a survival trial costing about $70M that the company runs and fails [UNVERIFIED — modelled] | UNVERIFIED — modelled |
| Base | +$5M | Value at approval $460M (base peak × 3.5 × 0.9) × 12% × about 0.64 for four years of discounting at 12%, less the risk-weighted trial cost | UNVERIFIED — modelled |
| High | +$250M | Value at approval $1,404M (high peak × 5 × 0.9) × 22% × about 0.8, the FDA accepting a filing without a new trial | UNVERIFIED — modelled |
No single figure, per 01-rules.md rule 10. The 5.10.3 range was $150–700M, before the FDA asked
for a survival trial. The market’s current valuation, about −$10M to −$25M of enterprise value
(../company.md C.4), sits at the bottom of this range.
B.4c Funding
| Question | Answer (tagged) [n] |
|---|---|
| Capital needed to the next decision point | Effectively nil to 2026-10-24; the data are locked [8]. |
| Capital needed to approval, and the funding plan | Not disclosed. A randomised survival trial in this disease would cost tens of millions and take years [UNVERIFIED — judgement]; Leerink estimated about three years of delay [35]. The $400M shelf and $100M ATM are unused (../company.md C.3). |
Cash runway against those needs (../company.md C.3) | $179.9M at 2026-06-30, “into 2028” by the company’s own guidance, which predates the FDA feedback (../company.md C.3). |
Financing need and dilution risk before the next decision (../company.md C.3, dilution history) | No raise is likely before 2026-10-24. After it, a raise at about cash value would be heavily dilutive. A partner is the other path. |
B.4d Launch, partnering, rights and economic share
| Question | Answer (tagged) [n] |
|---|---|
| Launch capability: can the company launch alone, or must it partner? | It has no product and no sales force, a Chief Commercial Officer since January 2026, and 39 staff (../company.md C.1a). A small US specialty launch is within reach; nothing beyond it. |
| Partnering history and comparable deal terms | ABL Bio in-licence and the Elpiscience China sub-licence (../company.md C.1a). No US or European partner. |
| Commercialisation rights: retained, split, or out-licensed? | US and rest of world retained, except South Korea (Handok) and China (out-licensed to Elpiscience) [1][2]. |
| Economic share | 0.9 [UNVERIFIED — judgement]. Basis: Compass keeps the US economics. It owes ABL Bio tiered single-digit royalties and up to $303M of commercial milestones in oncology [VERIFIED — Form 10-Q filed 2026-08-06] [1]. A mid single-digit royalty plus milestones spread over peak years leaves roughly 90%. |
Visual 4: scenario chart

Source(s): B.4a assumptions, launch assumed in 2029 with peak around 2034 [UNVERIFIED — modelled] [7][1]. Lines: low, base and high, in that order.
C. Risk
Framing questions
- Does the development plan support the target product profile claims (A.1)? For response rate and progression-free survival, yes. For survival, no: the design allowed crossover, and the FDA now asks for a trial that shows it.
- Would the identified risks change the target product profile? Yes. Without a survival result the regulator row of A.1 fails, and the payer row fails with it.
- If a risk cannot be mitigated, is the asset still differentiated from competitors? On response rate, yes. But a response-rate edge without a survival gain, at 44% severe high blood pressure, is a weaker product than FOLFOX in the eyes of the regulator.
| Risk group | Covers | Time / quality / cost risk | Likelihood | Impact | Mitigation | Source [n] |
|---|---|---|---|---|---|---|
| Science and clinical | Research, biomarker, clinical pharmacology, clinical efficacy, drug safety | Quality: flat survival, crossover-adjusted hazard ratio 1.13, no biomarker, 44% grade 3+ high blood pressure | high | high | None in hand. A safety signal of this kind is a near-veto for a drug with no survival gain. | [4][12] |
| Non-clinical | DMPK, safety pharmacology, toxicology | No toxicology finding found; the pharmacokinetics are modelled | low | low | — | [14] |
| Regulatory | Pathway, endpoints, review, post-marketing requirements | Time and quality: the FDA recommends a survival trial before filing | high | high | Further FDA engagement; a filing against advice | [4][10] |
| CMC and supply | Process, scale-up, comparability, capacity, diagnostics (from M) | Unnamed contract sites; validation spending that a delay could strand; aggregation risk in the format (M.6) | medium | medium | Standard CDMO qualification | [1][2] |
| IP and legal | Patents, freedom to operate, litigation, licences | Patents from 2033; ABL Bio terms; investigation notices without a filed suit | low | medium | Biologic and orphan exclusivity | [1][2] |
| Access and commercial | Evidence and value, payers, pricing, competition | No survival or quality-of-life gain against a generic | high | medium | Orphan pricing; a niche US launch | [5] |
| Execution and financing | Project management, clinical operations, funding, partners | Repeated slips; a survival trial needs money the shares cannot raise cheaply | medium | high | $180M cash; unused shelf and ATM | [1] |
The Risk profile domain is a direct score of 3 (red). Basis: the regulatory and the science rows are both high likelihood and high impact; execution and financing is high impact. · confidence Medium
Visual 5: risk heat map

Source(s): the risk table above [4][12][1][2]
Top-3 risks. 1. The FDA’s request for a survival trial before filing [4]. 2. Flat survival and the crossover check that made it worse [12]. 3. Severe high blood pressure in 44% of patients [12].
D. Look-back
Not applicable until settled. The look-back is written at settlement in lookback.md beside this
file (06-prompts.md § Settlement).
Readout
Sources
| Kind | Where it comes from | What it is worth | Value (or null) | Tag | Note |
|---|---|---|---|---|---|
bpiq | fetch_company_drugs, fields catalyst_date and catalyst_date_text | The one source every program has. On most rows it is built from period text, so on its own it is the latest plausible date (a ceiling), not an estimate. | 2026-10-24 | VERIFIED — BPIQ fetch_company_drugs 2026-10-17 | Text “October 24, 2026” names a day, so it is not a placeholder. catalyst_source is now the 2026-09-22 release. |
ctgov | CT.gov get_trial_details, field primary_completion_date | Independent of the company’s own messaging. Known to the month. It moves when the trial moves. | 2027-08-31 | VERIFIED — CT.gov NCT05506943, read 2026-10-17 | Moved from 2026-12-01 (read 2026-08-19). It dates the trial’s own completion, not the presentation. Recorded, not used for the window. |
company | fetch_company_press_releases | The company’s most recent dated statement. Also the source of the Date slippage table below. | 2026-10-24 | VERIFIED — Compass release 2026-07-17; 8-K exhibit 99.1 2026-09-22 | The July release gives Saturday 2026-10-24, 10:15–11:45 central European time, presenter Nilofer Azad [8]. The 2026-09-22 8-K reaffirms “the expectation to present the complete dataset at a medical conference this year” [4]. |
congress | data/congresses.json, only when the company has said it intends to present there (02-connectors.md § Data limits) | Answers where the result will be presented. | 2026-10-23/2026-10-27 | VERIFIED — data/congresses.json, ESMO Congress 2026 | Admissible because the company has said it will present there [8][39]. Supplies the window’s outer edges. |
modelled | Trial arithmetic, see below | The only estimate independent of anyone’s guidance. | 2027-10/2027-12 | UNVERIFIED — modelled, default lag | 2027-08-31 plus two to four months. Dates the trial’s final readout, a later and different event. Not used for the window. |
The modelled estimate. Registry primary completion 2027-08-31, plus the default two to four
months to database lock and analysis (01-rules.md rule 34), gives 2027-10 to 2027-12.
data/benchmarks/readout-lag.json holds no matching entry.
Window
| Earliest | Likeliest | Latest | Precision | Confidence |
|---|---|---|---|---|
| 2026-10-23 | 2026-10-24 | 2026-10-27 | DAY | HIGH |
Basis. The company named the day and time of the talk, and the BPIQ note and the 2026-09-22 8-K reaffirm it. The congress’s opening and closing days bound the window. The talk is on a Saturday morning in Madrid, so the first US trading session that can react is Monday 2026-10-26.
A correction to the 5.10.3 basis. That basis said the earliest date “additionally covers ESMO’s
own pre-congress abstract release making the headline numbers public on the opening day”. Neither
sweep verified ESMO’s 2026 embargo policy: the policy page returned 404 and the abstracts page loads
without text. One fact bears on it. On 2026-10-10 an OncoDaily preview listed abstract 459O and
quoted the already-public response and progression-free survival figures, but no duration of
response [6]. That fits an embargo until the talk. If ESMO instead publishes the abstract online
before 2026-10-23, the readout would come earlier than this window says. That risk is
[UNVERIFIED] and is carried in the Run-up exit choice below.
Disagreement. CONSISTENT. Three sources name the same day and the congress source brackets
it. The ctgov and modelled rows date a different event, the trial’s final completion. Kept from
5.10.3.
Date slippage. Five slips, unchanged since 2026-07-17. Every slip moved a reporting date; none was an enrolment delay. The two newest statements reaffirm October 24.
| As of | Guidance text |
|---|---|
| 2025-02-27 | ”Report topline data by the end of Q1 2025” |
| 2025-08-11 | ”Secondary endpoints including OS data expected in Q1 2026” |
| 2025-11-05 | ”OS/PFS secondary endpoint data expected late Q1 2026; potential first BLA filing planned H2 2026” |
| 2026-03-05 | ”PFS/OS secondary endpoint analyses from COMPANION-002 expected in April 2026” |
| 2026-04-27 | ”COMPANION-002 met key PFS endpoint; complete dataset with DoR to present later 2026; FDA meeting planned” |
| 2026-07-17 | ”Oral ESMO 2026 presentation of COMPANION-002 Ph2/3 BTC results on October 24, 2026” |
| 2026-08-06 | ”Final ORR 18%; FDA feedback Q3 2026; ESMO oral data October; BLA planned 2026” |
| 2026-09-22 | ”FDA advised survival-benefit trial before BLA; company will further engage FDA. ESMO data Oct 24, 2026.” |
Attribution
Status.
CONTAMINATED
Computed by attributionFor in lib/clustering.mjs over the six pipeline rows in
../company.md C.2, with CATALYST_CLUSTER_MIN_MONTHS = 6, for bpiq_drug_id
17398. Copied, not estimated.
Conflicts
| bpiq_drug_id | Label | Date | Analysed? | Gap (days) | Confirmed? |
|---|---|---|---|---|---|
| 17481 | CTX-8371 | 2026-12-31 | No | 0 | Yes |
| 18722 | CTX-10726 (PD-1 x VEGF-A bispecific antibody) | 2026-12-31 | No | 0 | Yes |
Note. Both conflicts are confirmed because this program’s own window is disclosed to the day. CTX-8371 and CTX-10726 carry only “Q4 2026”, which the module widens to the whole half-year from 2026-07-01 to 2026-12-31. So a known day sits inside two half-year windows. Either Phase 1 readout could land in the days around 2026-10-24. Both programs are rated meaningful in C.2, and the company’s value is now almost entirely cash plus these three programs, so a move in the stock-call window cannot be credited to tovecimig alone. A third event is not in the table because it is not a separate pipeline row: the company’s answer to the FDA, whose timing is unknown. Kept in substance from 5.10.3, which reached the same status from the same two rows.
Market and timing for this event
- Plain takeaway. The shares trade at the company’s cash. The market prices almost nothing for tovecimig after the FDA’s request. The 2026-10-24 talk will add one new number, the duration of response, and the first independent expert reaction. A good duration helps the case for a filing; it does not answer the FDA’s survival concern.
- Months to this catalyst. 0.2 months (6 days) from the 2026-10-17 lock to
readout.window.earliestof 2026-10-23. Precision isDAY, so this is a real countdown. - Expected move around this event.
../company.mdC.6 records the chain as unreadable: no strike at spot, and a $1.00 straddle quoted anywhere from 29% to 76% of spot. A bracket of ±10% to ±35% is used instead. Calibration: Phase 3 readouts average +11% and −22%, oncology +9% and −9%, and companies under $1 billion react 6.2 times more strongly at Phase 3[WEB ESTIMATE — IQVIA 2024]. This ticker’s own presentation-type events moved +0.8% to +11.0% over the event window, and its hypothesis-level events −35% and −65% (C.7). - Nearest comparable past reaction. C.7’s 2024-11-08 row, the CTX-471 congress presentation: +0.8% over the event window. It is the same kind of event, a talk on data already described. It is a poor match in size: a minor asset then, the only late-stage asset now, and a stock at cash with 25.6% of its float sold short now.
- Materiality.
../company.mdC.2 rates this program dominant. The stock call below is consistent with that. A dominant program presenting a known dataset, after the regulator has already spoken, is a smaller event than its materiality alone suggests. - Date slippage. Five slips; see Readout. None since 2026-07-17.
Spot. $0.86, the settled close of Friday 2026-10-16, read from data/prices/CMPX.json
through lib/prices.mjs after the 2026-10-17 fetch (../company.md C.4). It is a
settled close, not an intraday snapshot: it matches BPIQ’s last price and Yahoo’s daily close.
Cash floor.
| Cash floor (USD per share) | Cash, debt, quarterly burn (as of) | Event date | Economic share count | Residual pipeline value | Tag |
|---|---|---|---|---|---|
| $0.86 | $179.879M cash and securities, no debt, $14.738M quarterly burn (2026-06-30) | 2026-10-24 | 186,797,915 | $0 | UNVERIFIED — computed by lib/edge.mjs cashFloor |
cashFloor returns $0.86, net cash at the event of $161.2M over 1.27 quarters. At the first-half
average burn of $16.0M a quarter it would be $0.85. The residual pipeline value is $0, with a
reason. C.2 rates CTX-8371 and CTX-10726 meaningful, and rule 30 allows their value to be added.
No defensible figure exists for two Phase 1 assets with no partner and no deal comparable read this
sweep, so none is added (rules 9 and 10). The miss row’s basis says how they could hold the price
above the floor. Spot equals the cash floor.
Scenario prices
| Scenario | Low | High | Anchors (each named, tagged, with its kind) | Basis |
|---|---|---|---|---|
| Positive | $0.87 | $1.15 | (1) Cash floor $0.86 [UNVERIFIED — computed by lib/edge.mjs cashFloor] · cash_floor. (2) This ticker’s own positive data moves over the event window, median +1.0% (2025-04-01 +1.0%, 2024-11-08 +0.8%, 2024-08-12 +11.0%), which gives $0.87; maximum +11.0%, which gives $0.95 [VERIFIED — data/prices/CMPX.json event-window computation, ../company.md C.7] · own_past_moves. | The low edge is the price if the duration just reaches 5.0 months. It lands in the “missed expectations” bucket of 07-benchmarks.md: it clears the bar, but it falls short of the 6.9-month Korean figure and does not touch the FDA’s survival concern, so the shares stay near cash. The high edge is the price if the duration clearly beats 6.9 months and the discussant is supportive: the “significantly exceeded” bucket. It sits above the ticker’s own +11.0% maximum, for three named facts: 25.6% of the float is short (../company.md C.5); spot is the cash floor, so the stock prices no value for the asset; and a long duration is the company’s best answer to the FDA. Calibration: oncology +9% × 6.2 for a company under $1 billion [WEB ESTIMATE — IQVIA 2024]. Far below the commercial ceiling allowance of $6.77. |
| Miss | $0.62 | $0.84 | (1) Cash floor $0.86 [UNVERIFIED — computed by lib/edge.mjs cashFloor] · cash_floor. (2) This ticker’s own negative tovecimig moves over the event window, median −49.9% (2026-04-27 −64.6%, 2026-09-22 −35.2%), which gives $0.43 [VERIFIED — data/prices/CMPX.json event-window computation, ../company.md C.7] · own_past_moves. | A duration below 5.0 months, or none reported, removes the company’s best argument for filing. The range sits below the floor for named reasons: spending continues on three programs at about $15M a quarter; a Nasdaq bid-price notice can arrive from about 2026-11-19 (../company.md C.4); and an at-the-money ATM makes dilution cheap to start. It sits far above the −49.9% own-history anchor, because those two moves came from prices well above cash. Cash cannot be sold twice. The two Phase 1 readouts in Q4 2026 are what could hold it near the floor. The miss is shallower than the positive row is high, against the class default, because spot sits at the cash floor, the reason 07-benchmarks.md names as legitimate. |
Expectation benchmark. The Korean Phase 2’s 6.9-month median duration of response is the
only published reference point [7]. With the shares at cash, the market appears to price no route
to a filing at all [UNVERIFIED — judgement].
Expected value. 45% × the positive midpoint ($1.01) + 55% × the miss midpoint ($0.73) =
$0.856, or −0.5% against the $0.86 spot. Method: probability_pct applied to the midpoint
of each range. This is arithmetic, not advice, and not a price target.
Break-even probability.
| Break-even point | Break-even range (low–high) | Our probability (band) | Clearance (pp) | Call (callFromBands) | Evidence for the gap (each named and tagged) |
|---|---|---|---|---|---|
| 46.4% | 6.5%–96.0% | 45% (32%–58%) | none | no-edge — band [32, 58] overlaps range [6.5, 96] | None |
The range is 89.5 points wide because spot sits almost on the miss row’s high edge. The figure comes from our own scenarios, not from the market.
What a positive result can be worth.
| Value at approval (low / base / high) | Ceiling price | Allowance (1.5x, or 3x with a named exception) | Ratio to market cap |
|---|---|---|---|
| $90M / $459.9M / $1,404M | $4.80 | $6.77 (1.5×); $12.68 (3×, no exception claimed) | 1.556 |
Computed by commercialCeiling in lib/edge.mjs. Inputs: B.4a peak sales; economic share 0.9
(B.4d); the sales multiple of 2, 3.5 and 5 and the 1.5× allowance, both [UNVERIFIED — default];
the probability of approval after a positive Phase 2 readout, 52.4%
[WEB ESTIMATE — BIO/Informa/QLS 2021]; 186,797,915 shares; a $154.9M market cap. The Phase 2
figure is used instead of the Phase 3 one (90.6%), because the FDA’s request puts a confirmatory
survival trial ahead of approval. The ratio is high because the market cap equals cash. It is an
upper bound that assumes none of the program is priced in, which is literally true at this price.
Run-up
readout.precision is DAY and readout.confidence is HIGH, so date_confidence scores 100.
Rule 39 withholds a run-up call only when the precision is UNKNOWN. It does not apply here, so a
call is made.
Entry and exit
| Entry date | Entry price | Entry basis | Exit rule |
|---|---|---|---|
| 2026-10-17 | $0.86 | The lock date, a Saturday, at the settled close of Friday 2026-10-16. The first session in which the position could exist is Monday 2026-10-19. | T-2 trading days before readout.window.earliest, which resolves to the close of 2026-10-21. exit is null at lock: resolveExit returns null because the cache ends before the window. |
Why T-2 and not T-5. T-5 before 2026-10-23 is 2026-10-16, the entry’s own price bar. A T-5 exit would close the position before it opened. T-2 is chosen over T-1 to leave one more session before a possible early online abstract (Readout, correction).
Predicted move and peak
| Low | High | Estimated date | Basis | |
|---|---|---|---|---|
| Predicted move, entry to exit | −5% | +15% | — | Three sessions. For a rise: the price sits at cash with 25.6% of the float short (C.5), and a known Saturday event invites pre-positioning. Against: the shares fell from $1.02 to $0.86 over the past seven sessions, and tax-loss selling below $1 is a seasonal headwind. 07-benchmarks.md does not calibrate run-up drift. The band includes a loss because a band that excluded one would be a hope, not a forecast. |
| Predicted peak, from entry | +3% | +30% | 2026-10 | The peak may come after the exit, on Monday 2026-10-26, if the duration is good. The high edge matches the positive row’s high edge (+33.7%), less a little fade. |
Priority score drivers
| Driver | Reads | Score (0–100) | Basis |
|---|---|---|---|
| Unmet-need relevance | This document’s A.1 and B.1. A judgement, with no formula. | 85 | No approved drug for the 70–80% of second-line patients without a targetable alteration; FOLFOX adds 0.9 months of survival (B.1, A.1). Held below 100 because marker-selected subsets have drugs. |
| Value-uplift potential | stock_direction.commercial_ceiling.ratio_base, computed by valueUpliftScore in lib/edge.mjs. | 88 | commercial ceiling ratio R=1.556 (approval-adjusted value at a positive readout / market capitalisation), scored 80 + 40*log10(R), clamped to [0, 100]. High because the market cap equals cash. |
| Probability of a positive outcome | This record’s own outcome_prediction.probability_pct. Computed. | 45 | outcome_prediction.probability_pct = 45 |
| Date confidence | readout.precision and readout.confidence. Computed. It is the gate the other six drivers depend on (01-rules.md rule 39). | 100 | readout.precision=DAY, readout.confidence=HIGH |
| Squeeze mechanics | Float, short interest as a percentage of float, and average daily dollar volume. Computed. | 64 | float 157636355 shares, short_float_pct 25.6, average dollar volume 6226804. Float is the filed count less the 12.467% insider holding; short interest is FINRA’s 2026-09-30 count; dollar volume is the cache’s 20-session average volume at spot. |
| Priced-in-ness | 52-week position, price drift since the last catalyst, ownership crowding, and the spread between analyst targets. Computed. A HIGH score means room LEFT to run. | 99 | price 0.86 sits at 1% of its 52-week range (low 0.822, high 6.88, as of 2026-10-16) — closer to the 52-week low — room left to run. Reads in the opposite sense to its name: 99 means nothing is priced in. Only the 52-week leg is computed by the module. |
| Financing and clustering risk | Cash runway against the catalyst date, plus attribution.status and attribution.conflicts. Computed. The one NEGATIVE driver. | 100 | attribution.status=CONTAMINATED is the larger of the two independent risks (clustering). Reads in the opposite direction from the other five: 100 is the worst score and lowers the total. Runway alone (OK) would score 10. |
Priority score. From priorityScore in lib/runup.mjs.
Priority score 56 · formula_version 2.0.0
The 5.10.3 record scored 49 under formula 1.0.0. The two are not comparable: 2.0.0 computes value uplift from the commercial ceiling, which this low market cap inflates.
Settlement. Null at lock. Settled only on the user’s explicit request, from a confirmed primary
source, against the committed price cache (05-prediction-protocol.md § Run-up settlement).
Verdict
What I would do. Watch. Hold no position through the talk on these numbers.
Why. The shares trade at cash, so the downside from a disappointing duration is limited, and the upside from a strong one is real. The scenarios weigh those two almost exactly at today’s price: the expected value is −0.5% against spot, and our probability band sits inside a very wide break-even range. The FDA has already said what matters most for the asset. Patients did not live longer, and the crossover check made it worse. A duration figure, however good, does not answer that.
What would change this. A median duration of response of 9 months or more, with a discussant who backs a filing, would argue for the positive row’s high edge. An FDA statement that it will accept a filing without a survival trial would change the asset verdict. A duration below 4.7 months, the arm’s own median progression-free survival, would argue for the miss row’s low edge.
What to watch.
- 2026-10-19 to 2026-10-22: any online posting of abstract 459O before the talk.
- 2026-10-24, 10:15–11:45 central European time: the talk by Nilofer Azad, and the discussant’s verdict. The first independent named view of this dataset (A.2b).
- 2026-10-26: the first US trading session after the talk.
- About 2026-11-05: third-quarter results. Watch whether the runway “into 2028” is restated after the FDA feedback, and whether a survival trial is announced and funded.
- By 2026-11-14: third-quarter 13Fs, showing whether Tang, OrbiMed and Vivo held through 2026-09-22.
- From about 2026-11-19: the earliest date for a Nasdaq minimum-bid notice, if the price stays below $1.
- Q4 2026: CTX-8371 and CTX-10726 Phase 1 data, the two conflicts in Attribution.
- Q1 2027: the BLA target reported by secondary sources, not yet confirmed by the company.
Locked prediction
- Outcome-direction (will the readout succeed on its primary endpoint?): uncertain —
probability 45%, band 32–58%
[UNVERIFIED — modelled]. The definition below has three conditions. Two are close to settled: the final response rate is 18.0% [4], and the safety dataset was disclosed on 2026-04-27 [12]. The open one is a median duration of at least 5.0 months. The arm’s median progression-free survival is 4.7 months, and responders usually last longer than the arm as a whole, so 5.0 months is roughly an even bet. Two facts lean against it. The FDA saw the full data, duration included, and still asked for a survival trial. And the company’s 2026-09-22 rebuttal cited response rate, progression-free survival and survival subsets, but not duration [4]. That is why the figure moved down from 55% on 2026-08-19. No third party has published a probability on this event. - Base rate 47.7% (to the next phase, BIO 2021 Figure 2, p. 7, oncology) — distance
−2.7 pp. The base rate counts oncology Phase 3 programs that reached a filing. This call is
narrower: a duration threshold in a presentation of locked data. The figures sit close by
coincidence, not by derivation.
outcome_prediction.base_rateequalsasset_evaluation.pos.base_rate. - Stock-direction (which way do the shares move?): no-edge —
confidencenone — window 2026-10-19 to 2026-10-30. Basis: it opens with the first session of the congress week, covers the talk and the first trading session after it (2026-10-26), and closes before the expected third-quarter results. Materiality is dominant per../company.mdC.2. Attribution isCONTAMINATED: CTX-8371 and CTX-10726 carry “Q4 2026” windows that cover this day, so a move in this window is not attributable to this program alone. - Break-even probability 46.4%, range 6.5–96.0% — clearance none — gap evidence: 0 items.
- Cash floor: $0.86 per share.
- Scenario prices: positive $0.87–$1.15 · miss $0.62–$0.84.
- Commercial ceiling: $4.80 — positive high allowed up to $6.77.
- Expected value: $0.856, −0.5% against spot $0.86 (arithmetic, not advice).
- Run-up: entry $0.86 on 2026-10-17, exit rule T-2 trading days before
readout.window.earliest— predicted move −5% to +15%, predicted peak +3% to +30% around 2026-10 — priority score 56,formula_version2.0.0. - Settles on the ESMO Congress 2026 presentation of abstract 459O (scheduled 2026-10-24), its abstract, and any same-day Compass release or 8-K. Positive definition: all three hold. (1) A confirmed overall response rate for tovecimig plus paclitaxel of at least 15.0% in the primary-endpoint analysis, by independent central review where the presentation separates it from investigator assessment. (2) A median duration of response for that arm of at least 5.0 months. (3) No new grade 3 or higher treatment-emergent adverse-event category at a rate above the 44% grade 3+ high blood pressure reported on 2026-04-27. If no median duration for that arm is reported by 2026-10-27, the outcome is a miss. A duration “not reached” counts as at least 5.0 months only if the responders’ minimum follow-up is stated as at least 5.0 months.
- Locked: yes · Settled: no
Program data-quality flags
- The 5.10.3 positive anchor did not reproduce. The “+49.73% intraday” move on 2025-04-01 was
the 08-19 version’s upper bound for tovecimig news. The price cache gives +1.0% over the
protocol’s event window and +17.9% close to close (
../company.mdC.7 and C.8 row 3). This version’s anchors use the cache. - The 5.10.3 positive anchors are inadmissible under 6.2.0. That record anchored its positive row on the 52-week high and on analyst targets, and its miss row on the 52-week low. Rule 30 now bars all three. The old record is history and is not edited.
- The registry’s primary completion date moved by nine months between sweeps, from 2026-12-01 to 2027-08-31, with no stated reason [3]. Recorded, not interpreted.
- CT.gov carries no investigator names for NCT05506943.
search_investigatorsagain returned zero rows. A.2b is built from the design paper’s authors, matched to trial sites. - PubMed’s index mixes tovecimig’s code ABL001 with Novartis’s asciminib. A query including “ABL001” returned 389 hits; the real footprint is 4 papers. Kept as a warning for the next sweep.
- No conflict-of-interest statement is available for any named investigator. “No competitor relationship found” means the search had no disclosure section to read. One competitor tie was found from bylines instead (Goyal, futibatinib).
- No peer-reviewed clinical result exists. Every efficacy and safety figure traces to a company release or an 8-K. Kept from 5.10.3.
- The ESMO 2026 embargo policy could not be read. The policy page returned 404 and the abstracts page carries no text. The window’s earliest edge rests on the congress opening, and the 5.10.3 claim about an opening-day abstract release is withdrawn.
- Named correction to the PubMed reading. The 5.10.3 version said two of the four papers had ABL Bio employees as a majority of authors. That holds for PMID 33383646 (10 of 12). PMID 32580836 is Yonsei-led, with 6 of 13 authors from ABL Bio [34].
- The ABC-06 FOLFOX response rate (about 5%) and the 70–80% unselected share come from the 2026-08-19 sweep’s secondary sources, whose URLs it did not record. They are tagged as web estimates and drive no scored figure.
- The final response rate changed between sources: 17.1% (19/111, p=0.031) on 2026-04-27 [12], 18.0% (20/111, p=0.0228) on 2026-09-22 [4]. This version uses the later figure.
Sources
[1] Compass Therapeutics, Form 10-Q for the quarter ended 2026-06-30, filed 2026-08-06 — https://www.sec.gov/Archives/edgar/data/1738021/000117184326005295/cmpx20260630_10q.htm [2] Compass Therapeutics, Form 10-K for 2025, filed 2026-03-05 — https://www.sec.gov/Archives/edgar/data/1738021/000117184326001337/cmpx20251231_10k.htm [3] ClinicalTrials.gov, NCT05506943 (COMPANION-002), read 2026-10-17 — https://clinicaltrials.gov/study/NCT05506943 [4] Compass Therapeutics, Form 8-K exhibit 99.1, “Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback”, 2026-09-22 — https://www.sec.gov/Archives/edgar/data/1738021/000117184326006162/exh_991.htm [5] Lamarca A et al., “Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06)”, Lancet Oncol 2021 — https://doi.org/10.1016/S1470-2045(21)00027-9 [6] OncoDaily, “9 Hepatobiliary Cancer Trials to Watch at ESMO 2026”, 2026-10-10 (secondary) — https://oncodaily.com/gastrointestinal-oncology/esmo-2026-2 [7] Azad N et al., “COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC”, Future Oncol 2024;20(30):2241-2248 — https://doi.org/10.1080/14796694.2024.2351351 [8] Compass Therapeutics, press release, “Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026”, 2026-07-17 — https://www.globenewswire.com/news-release/2026/07/17/3329171/0/en/compass-therapeutics-announces-tovecimig-data-accepted-for-an-oral-presentation-at-the-esmo-congress-2026.html [9] Stocktwits, “Compass Therapeutics FDA setback raises concerns on Wall Street; H.C. Wainwright calls tovecimig filing strategy risky”, 2026-09-23 (secondary; the page returned 403 to a direct fetch, read through search summaries) — https://stocktwits.com/news-articles/markets/equity/compass-therapeutics-fda-setback-raises-concerns-on-wall-street-h-c-wainwright-calls-tovecimig-filing-strategy-risky/cZMEwFSRBJl [10] US FDA, draft guidance “Approaches to Assessment of Overall Survival in Oncology Clinical Trials”, August 2025 — https://www.fda.gov/regulatory-information/search-fda-guidance-documents/approaches-assessment-overall-survival-oncology-clinical-trials [11] CancerNetwork, “FDA Grants Orphan Drug Designation to Tovecimig for Biliary Tract Cancer”, 2026-04-08 (secondary) — https://www.cancernetwork.com/view/fda-grants-orphan-drug-designation-to-tovecimig-for-biliary-tract-cancer [12] Compass Therapeutics, press release, COMPANION-002 secondary endpoints, 2026-04-27 — https://www.globenewswire.com/news-release/2026/04/27/3281512/0/en/tovecimig-demonstrates-statistically-significant-benefit-in-companion-002-randomized-phase-2-3-study-in-patients-with-biliary-tract-cancer.html [13] OncLive, “FDA Grants Fast Track Designation to CTX-009 Plus Paclitaxel for Pretreated Biliary Tract Cancer”, 2024-04-25 (secondary) — https://www.onclive.com/view/fda-grants-fast-track-designation-to-ctx-009-plus-paclitaxel-for-pretreated-biliary-tract-cancer [14] Na JY et al., “Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor”, Cancer Sci 2024;115(12):3943-3951 — https://doi.org/10.1111/cas.16363 [15] DailyMed, ZIIHERA (zanidatamab-hrii) label, published 2026-08-27 — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae5d9425-fae5-4541-a158-150998343348 [16] DailyMed, PEMAZYRE (pemigatinib) label, published 2026-06-15 — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e1f2222-1d89-4e63-989c-ccebe2ab1eb4 [17] DailyMed, LYTGOBI (futibatinib) label, published 2026-06-02 — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b1332a1-0581-4707-9bf6-1eccfa39bef4 [18] Open Targets Platform, VEGFA and cholangiocarcinoma evidence (DLL4 has no association), queried 2026-10-17 — https://platform.opentargets.org/evidence/ENSG00000112715/MONDO_0019087 [19] ChEMBL, CHEMBL6068308 (tovecimig) — https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068308/ [20] Hyung J et al., “Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial”, JAMA Oncol 2023 — https://doi.org/10.1001/jamaoncol.2023.0016 [21] Harding JJ et al., “Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01)”, Lancet Oncol 2023 — https://doi.org/10.1016/S1470-2045(23)00242-5 [22] Abou-Alfa GK et al., “Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma (FIGHT-202)”, Lancet Oncol 2020 — https://doi.org/10.1016/S1470-2045(20)30109-1 [23] Goyal L et al., “Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma (FOENIX-CCA2)”, N Engl J Med 2023 — https://doi.org/10.1056/NEJMoa2206834 [24] Abou-Alfa GK et al., “Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy)”, Lancet Oncol 2020 — https://doi.org/10.1016/S1470-2045(20)30157-1 [25] FDA, Purple Book (searched 2026-10-17; tovecimig not listed) — https://purplebooksearch.fda.gov [26] DailyMed, TIBSOVO (ivosidenib) label, published 2025-12-22 — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=65d254c0-67ad-42c4-b972-ad463b755b2d [27] DailyMed, IMFINZI (durvalumab) label, published 2026-09-07 — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3 [28] ICER, assessments (searched 2026-10-17; no biliary tract cancer assessment found) — https://icer.org/assessments/ [29] Milliman, “Key takeaways: third Medicare drug price negotiation” (secondary) — https://www.milliman.com/en/insight/key-takeaways-third-medicare-drug-price-negotiation [30] CMS, Medicare Drug Price Negotiation — https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation [31] openFDA, complete response letter data API (queried 2026-10-17) — https://api.fda.gov/transparency/crl.json [32] openFDA, drug shortages API (queried 2026-10-17) — https://api.fda.gov/drug/shortages.json [33] Yeom DH et al., “ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models”, Int J Mol Sci 2020;22(1):241 — https://doi.org/10.3390/ijms22010241 [34] Kim DH et al., “Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer”, BMB Rep 2020;53(10):533-538 — https://doi.org/10.5483/BMBRep.2020.53.10.103 [35] BioSpace, “Compass vows to press on with FDA application despite new trial request”, 2026-09-22 (secondary) — https://www.biospace.com/drug-development/compass-vows-to-press-on-with-fda-application-despite-new-trial-request [36] Compass Therapeutics, second-quarter 2026 results, 8-K exhibit 99.1, 2026-08-06 — https://www.sec.gov/Archives/edgar/data/0001738021/000117184326005292/exh_991.htm [37] NICE, TA948, ivosidenib for previously treated advanced cholangiocarcinoma with an IDH1 R132 mutation — https://www.nice.org.uk/guidance/ta948 [38] William Blair, Compass Therapeutics initiation (secondary; figure read from search summaries) — https://www.williamblair.com/News/Compass-Therapeutics-Inc-Initiation [39] ESMO, ESMO Congress 2026 (via data/congresses.json) — https://www.esmo.org/meeting-calendar/esmo-congress-2026